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Chapter 1 - Background
Gynaecological cancers affect nearly 20 000 women annually in the United 
Kingdom1. They are a diverse group of cancers that are mostly only linked by 
their origin in the female genital tract. As such they vary in their stage at 
presentation, management and prognosis. Women with ovarian cancer are 
more likely to present at an advanced stage of disease than women with 
cancers further down the genital tract, due mainly to the late development and 
non-specific nature of the symptoms associated with this disease. As a result 
the overall five-year survival for ovarian cancer is only 41 %2. Women suffering 
from endometrial, cervical and vulval cancers tend to present at an earlier 
stage with symptoms of bleeding, discharge or pain (or through screening in 
the case of cervical cancer). This earlier presentation is reflected in the overall 
five year survival for these cancers: 75% (endometrial)3, 64% (cervical)4 and 
58% (vulval and vaginal)5.
Treatments vary according to the nature of disease. Ovarian cancer is 
primarily treated with surgery (simple hysterectomy, bilateral salpingo- 
oo p ho recto my, washings, omentectomy and debulking of tumour) and, in 
advanced cases with six cycles of platinum-based chemotherapy. Endometrial 
cancer is treated by surgery (simple hysterectomy, bilateral salpingo- 
oophorectomy and washings), with adjuvant brachytherapy or pelvic 
radiotherapy for those at higher risk of pelvic relapse. Cervical cancer is 
treated by surgery (radical hysterectomy and pelvic lymph node dissection) for 
early cases (in a third of cases adjuvant radiotherapy is required for those at 
high risk of relapse), but with primary chemoradiotherapy for the more 
advanced cases. Vulval cancer is usually treated by surgery (wide local 
excision with or without bilateral groin node dissection), with adjuvant 
radiotherapy given if there is spread of the disease to the lymph nodes or as 
primary treatment if there is involvement of adjacent structures such as 
rectum and urethra.
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As might be expected for a diverse group of cancers, patterns and frequency 
of recurrence also vary between the different gynaecological cancers. Ovarian 
cancer tends to present at a later stage than the other cancers, with over half 
of women having disseminated disease at the time of presentation. As a 
result, recurrence is more common in this disease. The treatment of recurrent 
ovarian cancer represents a challenge, as there are no curative interventions, 
with options invariably including chemotherapy, with a poor long term 
prognosis6. Whilst there is no curative salvage treatment for recurrent ovarian 
disease, in those previously responding to platinum based chemotherapy, 
surgery with or without chemotherapy offers an opportunity to produce 
significant periods of disease remission after recurrence7, it is difficult to 
extrapolate results in other malignancies to ovarian cancer, since it has a 
different natural history to both non-gynaecological cancer and other 
gynaecological cancers.
By contrast, recurrence in endometrial (13%)8 and cervical cancers is less 
common due to the earlier stage at presentation. Unlike ovarian cancer, there 
are potentially curative salvage treatments for a small proportion of these 
women. For women with recurrence after treatment for microinvasive 
carcinoma of the cervix, further surgical excision is usually possible. Women 
who are radiotherapy naïve and have localised pelvic recurrence can be cured 
with pelvic radiotherapy9. Those already treated with radiotherapy who have a 
central pelvic recurrence can, in certain cases, be saved by exenterative 
surgery. Localised recurrence in vulval cancer can be treated with further 
excision, if feasible, or radiotherapy if it is not.
As can be seen from this brief description, gynaecological cancers are a 
varied group of tumours with markedly different disease courses, treatments 
and prognoses. Their link is predominantly only the anatomical link of 
originating in the female genital tract. As such these cancers are managed 
individually according to the cancer site, the histology, the stage of disease 
and the individual patient needs.
5
Conversely the approach to follow up after treatment has tended to be less 
individualised. Traditionally, all patients who have been treated for cancer 
undergo long-term, even life-long, follow up in secondary specialist care. The 
primary rationale is that if a recurrence of the cancer is picked up early, it is 
more likely to be amenable to treatment and that therefore survival and/or 
quality of life will be improved10 11. It is regarded as standard practice to 
routinely follow up women after treatment for gynaecological cancer11 12 but 
this practice puts a significant strain on financial and workforce resources13'16. 
However, it has been suggested that the use of routine review may in fact 
delay the detection of recurrence because some women delay presenting 
symptoms until their next routine appointment17'19. Qualitative work has shown 
that women find routine visits to the hospital reassuring, especially if they are 
experiencing unexpected symptoms20. Never the less, for some, feelings of 
anxiety and apprehension may actually deter them from attending20.
Current Evidence
A systematic review by this author21 in 2005 demonstrated no prospective 
studies of follow up after any of the gynaecological cancers. An updated 
literature search of Medline up to August 2010 (table 1) demonstrated no 
prospective studies other than Rustin et al22 on the role of CA125 testing 
during follow up after ovarian cancer. Due to the lack of prospective studies, 
there are no data, other than in Rustin et al, on issues such as quality of life or 
meaningful economic evaluation.
Endometrial Cancer
There are no prospective studies, either observational or randomized.
Nine papers and one letter provide an analysis of the benefit of routine follow- 
up on survival13,15,16,23'29 Rates of recurrence varied from 8.5-19% of patients
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23„ Some of the papers limited themselves to early stage disease whereas 
others included patients with stage III disease (table 2).
Allsop, Agboola, Berchuck, Gaducci, Gordon, Owen, Podczaski, Salveson, 
Sartori and Shumsky all address the issue of whether routine follow-up 
produces improvements in clinical outcome, with survival as the 
endpoint13,15’16’23"28. Two of these papers26,29 conclude that there is a survival 
benefit from detection of recurrence at an asymptomatic stage. However, 
methodologically, both of these papers are very weak. No correction has been 
made in either for lead-time bias; the comparison is in survival times from 
detection of recurrence until death. There is also no attempt to correct for any 
differences in the known prognostic factors in the two groups. Hence the 
assertion from these two authors that there may be a survival benefit from 
routine follow-up is not reliable.
The remainder all correct for lead time bias13,15,16,23'25,27,28, by calculating 
survival as the time period from the original diagnosis to death rather than 
from recurrence of disease to death. They all conclude that there is no benefit 
in survival from detection of asymptomatic recurrence at routine follow-up, as 
opposed to symptomatic recurrence or interval detection. However all these 
papers are of poor methodological quality. They rely on restrospective 
collection of information and there is a risk that there may be a high proportion 
of patients with recurrence in amongst the patients that were lost to follow-up. 
The papers are heterogeneous, and comparison between them is difficult. The 
stage of disease varies and the strategies for follow-up (both the frequency 
and the use of routine investigations) show large variation. This may in part 
explain why there is such a large variation in the proportion of patients that 
were asymptomatic at the time of recurrence (8%-54%)15,25. Despite this, 
none of them show any benefit from routine clinical review. However it is 
possible that small differences in survival would not have been detected in 
view of the small numbers of patients with recurrent disease in these papers 
(table 2).
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A recent systematic review of follow up after primary treatment for endometrial 
cancer identified sixteen non-comparative retrospective studies8. This review 
set out to determine the most appropriate strategy for the follow up of patients 
with endometrial cancer who are disease free at the end of treatment. They 
pooled data to determine the risk of recurrence (13% overall and 3% for low 
risk disease). On pooled data, with one study excluded that would skew the 
results30, 70% of women were symptomatic at the time of detection of 
recurrence. No justification is given for the exclusion of the paper, which 
showed 100% of patients to be symptomatic at the time of recurrence.
Cervical Cancer
There are no prospective studies, either observational or randomized.
Ten papers14'31’32-36'29-37'38 were identified that considered the impact of follow- 
up after cervical cancer on survival in terms of survival benefit from detection 
of asymptomatic recurrence (table 4). All are retrospective case series 
analyses.
Zola reviewed 327 consecutive women with recurrent cervical cancer across 
eight institutions, identified from a central database38. The cases ranged from 
stage Ib1 to stage IV. They found a significant difference in median overall 
survival between women who were detected at an asymptomatic stage (109 
months) compared to those who were symptomatic (37 months, log rank 
p=0.0001). This paper contains the largest number of recurrences of any of 
the papers identified, but no data is given nor corrections made for any 
differences in prognostic features between the two groups. No data is 
provided as to whether the distribution of stages is similar across the two 
groups, let alone any other recognised prognostic indicators. Failure to 
consider prognostic indicators potentially introduces length time bias since it is 
likely that women with more indolent disease will have a longer time period 
with asymptomatic disease recurrence. This then creates the potential for 
women with more indolent disease to have a greater chance of having any
8
recurrence detected at an asymptomatic stage. Since indolent disease has 
better survival than more aggressive disease any difference in survival 
detected may be a reflection of type of disease rather than benefit from earlier 
detection. Hence it is likely that the difference demonstrated by Zola is an 
overestimate since the figure has to be subject to length time bias. 
Furthermore, this difference is made even more marked since this paper deals 
with a wider range of FIGO stages than the other papers identified. If these 
are not evenly distributed between the two groups then it will markedly bias 
the results.
Bodurka-Bevers et al demonstrated an apparent benefit in terms of survival 
from routine follow-up of women who had been treated for stage 1B 
carcinoma of cervix32. Primary treatment was either by radical hysterectomy 
or radiotherapy. The median survival from diagnosis differed significantly 
between asymptomatic recurrences (ja=83 months) and symptomatic 
recurrences (p, = 31 months) p<0.001. Furthermore this difference persisted 
when other prognostic factors (histology, grade, lesion size and lymph node 
status) were considered (p<0.01). This paper has the second highest number 
of cases of recurrent carcinoma (133), which may explain why this paper 
detected a significant difference in survival. However whilst the authors have 
corrected for known prognostic variables, with a retrospective paper, it is 
impossible to completely eliminate the possibility of length time bias producing 
this difference in survival.
Samlal et al also found a benefit from asymptomatic recurrence detection 
compared to symptomatic recurrence when comparing crude survival rates in 
these two groups (p=0.04)36. They looked at women with stage IB or stage HA 
cervical carcinoma who had been treated by radical hysterectomy. This was a 
much smaller study than Bodurka-Bevers, hence there were far fewer 
recurrences (27) in the group of patients being studied. Missing data may 
have had a profound effect on these results. There was no attempt to control 
for known prognostic factors. Hence it is quite possible that the two groups are
9
not directly comparable in terms of prognosis, leading to a high risk of lead- 
time bias and as such the results cannot be viewed as reliable.
Morice14 found no survival benefit from detection of recurrence at an 
asymptomatic stage in women who had been treated for stage I and stage II 
carcinoma of the cervix. This paper has a low number of recurrences, which 
may be due to the exclusion of 30 patients who had recurrent disease within 6 
months of the completion of treatment (which seems a very high figure). This 
paper also reports that 3 of the 7 asymptomatic recurrences were detected on 
radiological examination unrelated to routine follow-up, but no explanation is 
given for the indication for the examinations.
Ansink et al found routine follow-up to be inefficient and ineffectual in a case 
series of patients with stage IB cervical carcinoma treated by radical 
hysterectomy31, although no formal survival calculation is provided in the 
paper. Duyn found detection of recurrence at an asymptomatic stage not to be 
of prognostic significance33, nor did they find any benefit from detection at 
routine visits as opposed to interval detection. Krebs, Lim and Satori, in 
studies with similar numbers of recurrences though smaller total numbers of 
patients, also showed no benefit29,34,35, (Table 4). Larson did not formally 
compare the survival of women with symptomatic versus asymptomatic 
recurrence but the data tables show survival after recurrence to be similar (13 
versus 12 months)37.
A recent systematic review has attempted to establish best practice regarding 
follow up based on the existing evidence39. Elit et al determined that there 
was only modest low quality evidence to inform the most appropriate follow-up 
strategy39. They identified twelve studies14,29,31'38,40'46 that assessed the use of 
investigations to detect asymptomatic recurrence. Physical examination 
detected recurrence in this group of patients in 29-71% of cases. Chest x-ray 
detected asymptomatic recurrence in 20-47%, whereas CT detected 
asymptomatic disease in 0-34% (after exclusion of one paper with only two 
asymptomatic recurrences). Vault cytology found asymptomatic disease in 0- 
17%, but all other tests including ultrasound, MRI, intravenous pyelography
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and tumour markers were not of benefit39. However the papers do not always 
specify the site of recurrence. If it is assumed that the rationale for detecting 
asymptomatic recurrence is to improve survival then these papers do not 
determine whether or not there is benefit from these investigations, since 
survival is also dependent on the success of any salvage treatments available 
at relapse. As discussed above, there are potentially curative treatments for 
pelvic relapse but not, for example, from lung métastasés as would be 
detected by chest x-ray. It is also difficult to determine from the papers 
whether or not the investigations were performed solely with the intention of 
detecting asymptomatic recurrence or whether they were performed for some 
other reason. It is perhaps therefore not surprising that Elit questions the 
benefit of the routine use of investigations of any sort39.
Vulval Carcinoma
There are no prospective studies, either observational or randomized.
Only two papers were identified that examined the role of routine follow-up 
after vulval carcinoma18,19. Oonk et al reviewed the cases of 238 women with 
all stages of vulval carcinoma, who were disease free three months after the 
end of treatment19. They were followed up three monthly for two years, six 
monthly for three years then annually for life. 65 women developed 
recurrence, of whom 21 (32%) were asymptomatic at the time of detection. 
The median time to recurrence was 21 months (range 3-76 months). The 
comparison made was between women whose recurrence was detected at 
routine review and at interval review. The tumours detected at routine review 
were smaller, but this did not confer any survival benefit over those whose 
recurrence was detected at interval appointments (log rank test, p=0.22). The 
authors conclude that, although their retrospective study was unable to detect 
any improvement in morbidity, it may be that detection of smaller volume 
tumour recurrences may reduce treatment morbidity in this group. Hence 
follow-up may be of benefit.
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Nordin et al looked only at women who had node-negative squamous 
carcinoma of the vulva18. There were 138 cases who were followed up three 
monthly for the first year, six monthly for the second year and then annually 
for life. There were 18 recurrences (13%), all of whom were symptomatic at 
detection and 12 of whom recurred within the first year after diagnosis 
(median interval 8.7 months, range 1.0-85.4 months). The authors concluded 
that there was no evidence of benefit from routine follow-up in terms of early 
diagnosis of recurrence or improved survival. The issue of reduced morbidity 
from earlier intervention for recurrence is not addressed.
Ovarian Cancer
A recent review6 suggested that it is uncertain whether the early detection of 
recurrence is beneficial in terms of survival and the clinical advantage of an 
intensive follow up program has not yet been demonstrated. The use of 
CA125 for early detection of recurrence is widespread12,47, but the impact of 
this on the timing of chemotherapy has yet to be determined48,49. Only one, 
recently published, trial was identified22 by this author in a Cochrane review50.
0V0522
One relevant prospective study was identified22. This is a randomised 
controlled, multi-centre trial in ovarian cancer of early treatment of disease 
relapse based on CA125 level alone versus delayed treatment based on 
conventional clinical indicators (MRO OV05/EORTC 55955 trials). The trial 
registered 1442 patients; all women had confirmation of remission with normal 
CA125 concentration and no radiological evidence of disease after surgery 
and first-line chemotherapy. 529 women were randomly assigned to treatment 
groups at relapse detected by a rise in CA125, and were included in the 
analysis. All 529 were assessed at the end of the trial (265 early, 264 
delayed). The primary outcome measure was overall survival, calculated from 
date of randomisation to date of last follow-up or death from any cause.
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Women assigned to early treatment after relapse started chemotherapy 4 8 
months (95% Cl: 3-6 to 5 3 months) earlier than those allocated delayed 
treatment. The median length of follow-up was 56 9 months (interquartile 
range (IQR) = 37-4 to 81 -8 months from randomisation) and there were a total 
of 370 deaths (186 early, 184 delayed) in the trial. Median age at registration 
was 61 years (range: 53 to 68); 81% were FIGO stage lll/IV. Second-line 
chemotherapy started a median of five months earlier in the immediate arm. 
Chemotherapy treatment was given according to local institutional protocols. 
Median follow-up from randomisation was 49 months.
Health related Quality of Life (QoL) was reported by calculating time to first 
deterioration in QoL score or death using the EORTC QLQ-C3O 
questionnaire.
Toxic outcomes were not included as a secondary outcome measure.
Overall survival
Median survival from randomisation was 25-7 months (95% Cl: 23-0 to 27-9) 
for patients on early treatment and 27-1 months (22-8 to 30-9) for those on 
delayed treatment.
There was no statistically significant difference in the risk of death between 
women who received immediate treatment and those who received delayed 
treatment (unadjusted HR = 0-98, 95% Cl 0-80 toT20, p = 0-85). The 
unadjusted estimate was robust to estimates that were adjusted for 
stratification factors, prognostic factors and both stratification and prognostic 
factors (HR = 1-01, 95% Cl: 0-82 to 1 -25).
Quality o f life
Time from randomisation to first deterioration in global health score or death 
was shorter (median 3-2 months, 95% Cl: 2-4 to 4-3) in the early group 
compared with the delayed group (5-8 months, 95% Cl: 4-4 to 8-5; HR 0-71, 
95% Cl: 0-58 to 0-88; p = 0-002). The trial authors claimed that subgroup
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analyses of the QLQ-C30 sub-scales showed deterioration in score sooner in 
the early group than in the delayed group for almost all sub-scales. There was 
evidence of significant disadvantages for role, emotional, social, and fatigue 
sub-scales with early treatment. Furthermore the QLQ-C30 questionnaire 
asks about symptoms only in the previous week, and the forms were 
completed just before each course of chemotherapy. Hence this method could 
underestimate any reduction in quality of life due to chemotherapy.
Apart from 0V0522 all other studies in ovarian cancer on follow up strategies 
use the detection of recurrence as the primary endpoint. This is problematic, 
as time to detection of recurrence is not an adequate surrogate marker for 
overall survival. The two may diverge depending on treatments available at 
relapse. Furthermore detection of recurrence without subsequent information 
on survival risks the introduction of lead-time bias.
Clinicians’ and Patients’ Views
Two studies in the gynaecological oncology field have addressed clinicians 
views and practice with regards to follow up11,12. Kerr-Wilson showed that, in 
the early 1990s, there appeared to be five rationales for following women up 
after treatment:
• detection of recurrence 
e reassurance for patients
• audit, research or collect statistics
• assess side effects
• tradition
Barnhill showed that there was wide variation in the use of investigations to try 
to detect recurrence12. However, all investigations were analysed with a view
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to whether or not they successfully detected recurrence, rather than whether 
or not this had any impact on the overall outcome.
A large recent quantitative survey of nearly 3000 service users51, primary care 
physicians and specialists with experience of all types of cancer has shown 
that these groups regard the main reasons for follow up as being:
• to monitor for early complications
• to detect recurrences early
• to detect late effects of treatment.
Service users were significantly more likely to view detection of recurrence as 
highly important than were medical staff. Primary care physicians were more 
likely to view early detection of recurrence as important than were hospital 
specialist staff.
Kew et al also showed, in a sample of gynaecological oncology patients 
undergoing follow up, that patients regard detection of recurrence as the 
primary rationale for follow up, and that they rate this more highly than 
clinicians do52.
Bradley et al showed, with a qualitative study of women with early stage 
gynaecological cancers, that women value follow up because it affords them 
ready access to specialist services20. The women described a feeling of 
increasing apprehension in the lead up to their appointments, but placed huge 
value on the reassurance derived from attending the appointment. She also 
demonstrated that women valued scans above all other investigations in 
determining their disease status.
A study using focus groups also showed that the patients viewed follow up 
visits as reassuring53. They were reluctant to consider follow up by General 
Practitioners or telephone follow up. This is in keeping with a quantitative 
study by Kew et al54. However a focus group of professionals working in 
medical oncology53 felt that the main rationale for hospital-based follow up
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clinics was to monitor the patients for symptoms of relapse. They also felt that 
the current system of routine follow up was unnecessarily labour intensive and 
needed reform, whilst recognising that patients may be reluctant to have 
shared care with their General Practitioners. However, improved 
communication may be required if such a change were introduced since less 
than half of General Practitioners were satisfied with aspects of 
communication regarding their patients who have been treated for cancer55.
Alternative Models
Due to the lack of prospective work, alternative forms of follow up have not 
been investigated in women who have been treated for gynaecological 
malignancies. Follow up strategies using models other than the traditional 
secondary care model have been examined in patients following treatment for 
other malignancies. Follow-up by general practitioners has been shown to be 
effective and acceptable in breast cancer56. An equivalence trial in breast 
cancer comparing nurse delivered telephone follow up with traditional hospital 
follow up showed that there was no adverse outcomes in terms of physical or 
psychological outcomes, but did not assess survival57. A pilot study making 
use of open access after breast cancer was popular with the patients58, but a 
full randomised trial was not funded. The use of specialist nurses has been 
reported to be safe and effective following lung cancer59.
Work in women who have had a gynaecological malignancy has suggested 
that what they seek at follow up is reassurance from a cancer specialist20. 
This is further confirmed by Kew et al, who showed that women already 
undergoing follow up in secondary care prefer to continue to have review by a 
specialist, rather than being seen by a specialist nurse only or their General 
Practitioner54. It is difficult to determine whether or not this is due to pre­
existing expectations in women who are already used to this sort of follow up, 
and there is evidence in a survey of service users in all fields of oncology that 
they rate most types of follow up highly if they have experienced it51. As such
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it may be that introducing different sorts of follow up will require significant 
patient education for those who are already in a given follow up regimen.
Conclusions
All papers assessing follow up after gynaecological cancer are retrospective 
and so are subject to significant bias. Whilst the better papers correct for lead- 
time bias and attempt to correct for length time bias, it is impossible to 
completely eliminate this from a retrospective non-randomised study. Many of 
the studies have small numbers of recurrences so it is impossible to be sure 
that significant differences in survival are being missed in these papers. It is 
also impossible to retrospectively assess the impact of different sorts of follow 
up on quality of life.
The majority of the papers found deal with patients who have been treated for 
early stage malignancy. The use of the term ‘recurrence’ implies that the 
women who were included were disease free at the end of treatment. There is 
virtually no data on patients with more advanced disease, whose needs may 
be very different. For these women, the primary rationale behind routine follow 
up -  that of detecting and treating recurrent disease early -  does not apply. 
Therefore it may be more appropriate to provide direct access than routine 
review. This may offer these women better support and quality of life, but 
further work is needed to determine any such benefits.
Plan of work
As has been shown with this review, prospective studies are required to 
assess the impact of follow up in women who have been treated for 
gynaecological cancer. A large multi-centre randomised controlled trial should 
be initiated to compare the current routine follow-up schedule with an 
alternative system of follow up, such as patient self-referral based on their 
symptoms. The execution of such a trial has been shown to be acceptable to
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General Practitioners60. This would allow the question of whether or not 
routine clinical review in secondary care improves survival, compared to 
presentation at the time of symptomatic relapse, to be answered. Such a trial 
would also allow determination of the impact that routine follow-up has on 
quality of life. There are examples of randomised trials in other, more 
common, malignancies such as breast and colon. These trials confirm that 
patients can be recruited into this type of trial58,61,62.
In order to develop the protocol for a randomised trial, specific pieces of work 
were needed.
Work stream 1 : Audit of practice
In order to determine the baseline for a trial, it was important to determine 
what was ‘standard’ practice regarding follow up. This was to be determined 
using a quantitative questionnaire developed specifically to collect the 
information considered necessary for the development of a ‘standard care' 
arm in the full trial.
Work stream 2: Women’s views
There is a lack of data on women's views of follow up after gynaecological 
cancer, especially in more advanced disease. In order to develop an 
intervention arm for a randomised trial it was necessary to understand how 
women view the current arrangements and the benefits and/or drawbacks 
they see with it. Given the lack of data in this area, a qualitative approach was 
planned in order to explore and understand the issues for women undergoing 
follow up, such as ‘why?’ and ‘how?’ rather than ‘how much?’63.
18
Work stream 3: Pilot Randomised Controlled Trial
A pilot randomised trial was planned to determine the feasibility of recruiting to 
and running a multi-centre randomised controlled trial. The null hypothesis for 
such a trial would be that there is no benefit from follow up.
19
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Chapter 2 -  Survey of Practice
Introduction
Current practice with regards to follow up after gynaecological cancer in the 
United Kingdom is unknown. A previous survey of gynaecologists conducted 
in the United Kingdom in 1995 revealed 106 different schedules of follow up11. 
However, this was prior to the centralisation of all cancer services in the 
United Kingdom64. The Calman-Hine report introduced the concept of hub and 
spoke arrangements for cancer services, where rare cancers such as the 
gynaecological cancers were to be managed via a network with one cancer 
centre supported by several cancer units. Diagnostic work and some low-risk 
cancers can be managed in the units with all more complex cases referred on 
to the centre for management by subspecialists65. Centralisation resulted in 
profound changes to the way care for women who have gynaecological 
cancer was delivered. Care for all cancers is now delivered on the basis of a 
wheel and spoke arrangement, with care organized into networks with a 
cancer centre supported by cancer units64. Further guidance on 
commissioning care for women with gynaecological cancer included 
recommendations on follow up65. These stipulated that there should be 
guidelines on follow up in each cancer network, and that routine follow up 
should not be considered mandatory for women who are in complete 
remission after curative treatment for endometrial cancer. It also 
recommended that vault smears should not be used to detect recurrent 
endometrial cancer. However, beyond this there are no standard 
recommendations on the frequency or duration of follow up, nor on the use of 
routine investigations during follow up such as x-rays, Computerised 
Topography (CT) scans, Magnetic Resonance Imaging (MRI) scans or tumour 
markers (specifically CA125 in ovarian cancer).
Following these changes there had been no data or assessment of practice 
with regards to follow up in the United Kingdom. However, the United
24
Kingdom has devolved health to its constituent states and so there are now 
four separate health services. It was therefore decided to assess follow up in 
by far the largest health service, the English National Health Service66. This 
project set out to determine current practice of follow up after gynaecological 
cancer in the 34 English Cancer Networks.
Methods
A two-page questionnaire (appendix 1) was developed in consultation with a 
consultant gynaecological oncologist and a statistician. It was piloted within 
the department of gynaecological oncology and James Cook University 
Hospital to ensure it was easy to understand and complete.
The aim was to send out one copy of the questionnaire to the lead clinician for 
gynaecological cancer in each cancer centre. However, at the time of the 
study, it was impossible to establish an accurate list of these individuals. 
Hence the survey was limited to English Gynaecological Cancer Centres only. 
No authoritative list was available, either on line or from the Department of 
Health. A list of the cancer networks and their gynaecological cancer centres 
was used which was obtained at a national meeting of the British 
Gynaecological Cancer Society. A contact point was established in each 
centre through a series of telephone calls and by indentifying individuals at 
national meetings.
In total 37 questionnaires were sent out to the 34 cancer centres. The 
duplication was due to the lack of a database of gynaecological cancer leads. 
Questionnaires were sent out by post, followed by another postal round to 
non-responders eight weeks later. This was followed up by distribution of the 
questionnaire at a face-to-face meeting of gynaecological cancer leads and it 
was then distributed by email to non-responders. Results were analysed using 
the Statistical Package for Social Sciences.
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Results
Of the 37 questionnaires sent out, 25 replies were received from 24 different 
cancer networks. One response was excluded because it was from a cancer 
unit, where a response was received from that network’s cancer centre. One 
reply was received from a cancer unit in a network where there was no 
response from the centre. Since networks are meant to have network 
guidelines including on follow up, this response was therefore included. The 
overall response rate was 24/34 networks (71%). 23/24 (96%) responses 
were from cancer centres.
All networks provide some routine follow up after gynaecological malignancy. 
Only one network reported curtailment of follow up at an early stage. They 
described reviewing patients twice in the first year after treatment and then no 
routine follow up in a clinic, but providing them with open access instead. In 
total 6/24 (25%) reported using open access as part of their follow up service. 
All routine follow up took place in secondary care, and was consultant based 
(table 2.1). In the majority of cases, there was also a specialist registrar in the 
clinic (15/23; 65%). 18/24 (75%) of networks had written guidelines on the 
frequency and timing of follow up.
The commonest follow up regimens are presented in table 2.2. 10/24 (42%) 
networks used the same follow up frequency and duration irrespective of the 
primary cancer site (ovary, endometrium, vulva or cervix), whereas the 
remainder varied according to the diagnosis. Overall results of frequency of 
visits are shown in table 2.3.
The stated duration of follow up is shown in table 2.4. Apart from the network 
mentioned above, that discharges patients from routine follow up after one 
year, three other networks (12.5%) described discharge from routine follow up 
within five years of completing treatment. One network discharged women 
who have been treated for cancer of the ovary, endometrium and cervix after 
three years of follow up. Another network discharged women who have been
26
treated for endometrial cancer after three years and a third discharges women 
who have been treated for cervical cancer after two years.
Very few routine investigations were undertaken to detect recurrence. The 
exception was Ca125 levels following treatment for ovarian cancer. 16/24 
(67%) networks routinely performed this test at each routine review. One 
network used annual CT to check for recurrence after treatment for cervical 
cancer. No other routine investigations were recommended.
Overall it can clearly be seen that the most favoured follow up regimen was 
secondary care follow up by consultants with the patients attending 3 monthly 
for the first year, 3 or 4 monthly for the second year, 6 monthly for the third 
and fourth years and then an annual visit until discharge at 5 years. There is 
an inclination to follow up women who have been treated for ovarian cancer 
slightly more often than for the other cancer sites. For women being followed 
up after ovarian cancer, serum CA125 measurement was recommended at 
each follow up visit.
Discussion
This survey provides an up to date assessment of current practice in England 
with regards to follow up after gynaecological malignancy. It clearly 
demonstrates that the large majority of networks are continuing to follow up all 
women who have been treated for gynaecological cancer for at least five 
years, and in several cases for longer periods of time. In 1999 the Hayward 
report65 stated that there was no evidence to support the routine follow-up of 
women in remission after a gynaecological cancer, and suggested that follow- 
up of women after endometrial cancer should not be considered mandatory.
Our survey demonstrates that 25% of networks are failing to follow 
recommendations that there should be a documented policy on the frequency 
and timing of follow up for each type of gynaecological cancer65. This may be 
because of a lack of good quality evidence on the best regimens for follow up.
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There is no prospective data in the medical literature regarding the impact of 
routine follow up on survival after treatment for gynaecological malignancies21.
It has been suggested that the use of routine review may in fact delay the 
detection of recurrence because some women delay presenting symptoms 
until their next routine appointment17. For some women, feelings of anxiety 
and apprehension may actually deter them from attending20. However 
qualitative work has shown that women find routine visits to the hospital 
reassuring, especially if they are experiencing unexpected symptoms, 
although the reassurance only lasts for short periods of time20. Whilst there 
have been moves with other cancer sites to use different forms of follow-up 
such as nurse led59 or General Practitioner led67, practice in gynaecological 
cancers has been shown to still follow the traditional secondary care model, 
with periodic review of decreasing frequency.
Van Voorhis wrote, in 1970, that ‘the value and most desirable frequency and 
duration of follow-up examinations for patients with cervical cancer is not well 
established’68. The variability in regimens demonstrated in this paper seems 
to demonstrate that, 35 years later, clinicians remain uncertain as to how and 
when to follow women up after treatment for gynaecological cancer.
Validity
The aim of any survey is to gather valid, reliable, unbiased and discriminatory 
data from a representative sample of respondents, or in the case of a census 
from an entire population. However, the data collected are subject to error and 
bias from a range of sources. Our close attention to issues of questionnaire 
design and survey administration aimed to reduce these errors69. However 
research in to this methodology is limited and the heterogeneity of findings 
mean that there are no universal recommendations on best practice in terms 
of either questionnaire design or survey conduct69.
Sampling
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There are several alternative sampling options to the one that was utilised 
which may have influenced our results. Firstly, a survey could have been 
undertaken of all gynaecologists and their practice in relation to follow up, 
similar in nature to previous work in this area11. However the changes in 
provision of service mean that most gynaecologists no longer undertake care 
of women with gynaecological cancer, nor do they contribute to the provision 
of follow up. As such any results would not have been valid as the population 
sampled would have been inappropriate for the data collected.
A second option would have been to survey all gynaecological cancer centre 
leads and gynaecological cancer unit leads. This would have permitted 
evaluation of follow up procedures throughout the cancer networks, rather 
than determining the practice in the cancer centres. In theory practice should 
be standardised throughout each network with the use of guidelines65, but, as 
this project showed, 25% of responding networks did not have written 
guidelines on follow up. There is also no evaluation of adherence to the 
protocols reported by the cancer centre leads. However assessment of 
compliance, whilst interesting, was not possible. In terms of surveying all 
cancer unit leads as well as cancer centre leads, practical considerations 
meant that a survey of that nature was unlikely to produce useful results. As 
described in the methods section of this chapter, the author found great 
difficulty in determining the whereabouts of the gynaecological cancer centres 
for each cancer network and then identifying a lead clinician within that 
service. Therefore to attempt to identify the gynaecological cancer units that 
feed in to the centres, and their lead clinicians, would have been unfeasible 
and unachievable.
Survey administration
There are essentially three options for survey administration: face-to-face 
interviews, telephone interviews and postal questionnaires (paper and/or 
electronic). The use of face-to-face interviews was impractical for this project 
as it would have required travelling to the 33 other gynaecological cancer 
centres.
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Telephone interviews were a potential option. They are usually more effective 
than postal questionnaires at avoiding refusal, and they guarantee knowledge 
of which individual is completing the questionnaire. They also improve item 
non-response rates. However they may introduce bias from the views and 
characteristics of the interviewer and are more expensive to perform69. This 
study was not specifically interested in the views of individual clinicians, but 
rather the standardised practice of the department. As such one of the main 
benefits of telephone questionnaires does not apply to this survey. Strategies 
for enhancing response to a postal questionnaire are discussed below.
Questionnaire Design
The questionnaire was designed around standard recommendations70. 
Previous work by other researchers using open questions11 were used to 
inform the development of this survey. Short questions requiring specific 
answers were used in order to standardise the data collected. Technical 
language was used, but only standardised terms were employed, such that 
any professional in this field would reasonably be expected to understand the 
question. Leading questions were avoided except where specific information 
was required (eg ‘do you provide open access). ‘Other’ was included as an 
option so that unexpected responses would be captured. No opinions were 
sought so issues around response format were not relevant.
The questionnaire would have been enhanced had the questions stated ‘the 
cancer centre in which you work’ rather than ‘you’, since the term ‘you’ can be 
misinterpreted70. This may be particularly relevant for the 25% of centres 
where there are no guidelines in place and the follow up regimen may be 
specific to the consultant completing the form, rather than the department.
The questionnaire was designed to be only two pages of A4 paper in length, 
recognising that the people completing the forms are busy clinicians who may 
be put off completing a long survey. However length of survey has not been 
shown to affect response rates in studies outside of the health field 69. 
Significant amounts of ‘white space’ were used so that the survey appeared
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easy to fill in and the questions did not appear cramped 69, although the 
benefit of this strategy is not proven.
Response Rates
The response rate for this survey was 71%, which Mangione71 would rate as 
Very good’. Typically, response rates reported in the medical literature are low 
and surveys of physicians are lower still (on average 54%)72.
Several approaches were adopted to maximise response rates. Firstly the 
questionnaire was kept brief. Secondly, reminders were sent to stimulate 
further responses, which has been shown to be effective at maximising 
response rates69. A return envelope was included in order to facilitate easy 
return of the questionnaire although, due to financial constraints, these were 
not stamped. The effect of providing a stamped envelope for return is 
equivocal69. Anonymity was not offered as it was necessary to identify non­
responders so that reminders could be sent. Anonymity has not been shown 
to significantly improve response rates69 and furthermore the information 
being collected was not personal in any way and in many cases is already in 
the public domain. Pre-notification has been shown to increase response 
rates, but was not used in this project, again because of cost limitations. 
Contacts were limited to reminders as they tend to be more effective in 
enhancing response rates than pre-notification.
Implications for Research
This survey was undertaken in order to provide information on current practice 
so as to determine the ‘standard follow up arm' for a randomised controlled 
trial of follow up in women who have been treated for gynaecological 
malignancy. It can be clearly seen that such a regimen would consist of 
consultant review in secondary care. The most common schedule was three
31
monthly for the first year, three or four monthly for the second year, six 
monthly for the third year and then annual review until five years.
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Tables
Table 2.1 grade o f staff reviewing patients in the follow up clinic; n=22
Grade of staff N (%)
Consultant only 7 (30%)
Consultant and specialist registrar 15(62%)
Consultant and staff grade doctor* 2  (8 %)
General practitioner 0
Senior House Officer** 1 (4%)
Clinical Nurse Specialist** 5(21%)
* One clinic included consultant, specialist registrar and staff grade doctor
** Present in addition to the consultant
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Table 2.3 Recommended frequency of visit by cancer site
Recommended 
visits per year
Year 1 Year 2 Year 3 Year 4 I Year 5
Number of survey respondents
Ovary 0 0 1 1 2 2
1 0 0 3 7 9
2 1 2 10 12 10
3 1 9 6 1 1
4 21 11 3 2 2
5 0 0 0 0 0
6 1 1 1 0 0
Endometrium 0 0 1 1 3 3
1 0 2 5 11 14
2 2 6 13 9 6
3 3 10 3 0 0
4 17 4 1 0 0
5 1 0 0 0 0
Vulva 0 0 1 1 1 1
1 0 0 3 9 11
2 2 5 13 12 1 0
3 3 10 3 0 0
4 16 6 2 0 0
5 1 0 0 0 0
Cervix 0 0 1 2 3 3
1 0 0 2 10 13
2 1 3 14 10 7
3 2 12 3 0 0
4 20 7 2 0 0
Commonest responses are in bold type
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Table 2.4 Duration of follow up (n-24)
Cancer site 5 years 10 years Lifelong
Ovary* 15 y** 1
Endometrium 22 2 0
Vulva* 17 4 2
Cervix 19 5 0
* data missing in one case
** two networks followed these women up six monthly; in all other cases the 
review beyond five years was annual
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Appendix 2.1 - Survey of Current Follow Up Practice 
Follow-up After Gynaecological Malignancy 
A survey of current practice
Do you routinely follow up patients after treatment for gynaecological 
malignancy?
Yes/No
If no, do you provide open access? Yes/No
Please give details:
If yes, where does this routine follow-up take place?
Hospital clinic □
General Practice □
Other (please specify)...................... .......................... ..
Who sees the patient for follow-up (tick all that apply)?
Consultant □
Consultant or SpR □
Consultant or Staff Grade □
General Practitioner □
Other medical staff (please specify) ........................................
Clinical Nurse Specialist □
Other (please specify)................................. ....................................
Do you have written guidelines on the recommended frequency of routine 
follow-up after treatment? Yes/No
If yes, please include a copy of these guidelines when you return the questionnaire.
What is the recommended number of visits per year in each of the cancer groups (eg 
3 monthly visits equates to 4 visits per year)?
year 1 year 2 year 3 year 4 year 5
Ovary □ □ □ D 0
Endometrium □ □ □ □ 0
Vulva □ □ □ □ □
Cervix □ D □ □ 0
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Do you routinely carry out investigations in order to detect recurrence? 
In ovary yes/no
specify  .........................................................
In endometrium yes/no
specify...........................................
in vulva yes/no
specify.............................. ............
In cervix yes/no
specify............................. .............
Do you follow patients up for more than 5 years?
Ovary Yes/No
If yes, for how long? ...........
And how often? ...........
Endometrium Yes/No
If yes, for how long? ...........
And how often? ...........
Vulva Yes/No
If yes, for how long? ...........
And how often? ...........
Cervix Yes/No
If yes, for how long? .... ......
And how often? ..........
Name of person completing the form
Designation....................................
Cancer Centre................................
Lead clinician for Gynae Cancers....
Thank you for your help
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Chapter 3 -  Women’s Views of Follow up
Introduction
It is increasingly recognised that the views of patients are vital to the 
establishment and design of healthcare services 65,73. Despite this, very little 
has been published on women’s views of follow up after treatment for 
gynaecological cancer. Only one piece of qualitative work has previously been 
undertaken in women who were having follow up after a gynaecological 
malignancy20. However this piece of work was carried out in women who had 
had early stage disease, and in all 4 main gynaecological cancers. It showed 
that the main element of follow up from the woman’s point of view is the need 
to receive medical reassurance that there is no recurrence of the disease. 
This would not seem to fit with the high proportion of patients (75%) who were 
willing to accept nurse-led follow up in another study59. Furthermore, no 
qualitative work has been undertaken in patients receiving any model of follow 
up other than traditional, medically-based, routine clinic review. It is well 
established that qualitative studies offer an alternative when insight into the 
research is not well established or when conventional theories seem 
inadequate74.
In terms of quantitative research, there is only a limited audit which showed 
that 32% of women preferred hospital follow up, 28% would prefer follow up
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with a General Practitioner and 40% would prefer ‘free access’75. However, 
the views of patients already in medical follow up on the role of specialist 
nurses in follow up has not been investigated, nor has their understanding of 
the reasons for follow up.
The aim of this study was to collect information on women’s views of follow 
up. This was done in two ways. Firstly in-depth information was collected 
using qualitative methodology and this information was then triangulated76 
with quantitative data collected via a questionnaire. The information was then 
used to inform the design of follow up strategies suited to the expressed 
needs of women who have experienced follow up.
Methods
Qualitative Study
The qualitative study aimed to investigate the views, needs and experiences 
of women who had received three different models of follow up after treatment 
for ovarian cancer in a tertiary referral Gynaecological Cancer Centre.
The first model was standard follow up, as described in chapter 2. Patients 
typically attended for review 3 monthly in the first year, 4 monthly in the 
second year, 6  monthly in the third year and then annually until discharge at 5 
years. At each appointment they would have a medically based history taken, 
an abdominal and vaginal examination and, more often than not, blood taken 
to determine the CA125 (tumour marker) level. The second group of women 
were participating in the MRC 0V05 study22. They were also included in order
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to ascertain any impact from this trial on women’s views. 0V05 was a blinded 
randomised controlled trial comparing early treatment of recurrent ovarian 
cancer based on tumour marker (CA125) relapse, compared with treatment at 
symptomatic relapse. Follow up within the trial protocol required two monthly 
clinic review with clinical examination and a blood test at each review. The 
third model was of nurse-led telephone follow up, which took place within the 
TRIFIDS trial (ethics reference 77/01) (trial never completed or published). 
The TRIFIDS trial compared intensive follow up (intensive by virtue of the use 
of CA125 and CT scans to detect recurrence early) with nurse-led telephone 
follow up (this trial was stopped early because of political problems and has 
never been published). Those who were allocated to nurse led follow up were 
telephoned by a specialist nurse every three months and asked a series of 
questions about their health. If there were symptoms suggestive of recurrent 
disease, they were invited to a clinic appointment to have an examination and 
investigations.
Qualitative methodology was used in order to investigate the detailed 
experiences and views of a broad cross section of women who were 
undergoing follow up after ovarian cancer. Specifically, grounded theory was 
used in order to develop a more in-depth understanding and explore the lived 
experience from a patient perspective and analyse the data through the 
iterative process of constant comparative analysis77. Interviews were semi­
structured, based on themes previously identified by medical staff, nursing 
staff and patient groups (Appendix 3.1). Medical and nursing staff identified 
themes during informal discussions and formal research feedback sessions.
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Patients’ views were identified from previous research20. Interviews were tape 
recorded and then transcribed by a secretary in order to permit reference to 
the source data and allow the researcher to become immersed in the world of 
the sample being studied. Data collection continued until data saturation had 
been reached. It was estimated that this would require ten women to 
participate. Data saturation is described as being achieved simply when 
further interview data produces no new themes or perspectives77.
Women were identified to take part in the study from clinic lists of attenders for 
routine follow up, from the list of participants from the TRIFID study, and from 
the list of women in the department who were participating in the 0V05 study. 
All women who had completed treatment for ovarian cancer and were 
undergoing follow up were potentially eligible for the study. The only exclusion 
critérium was women who did not speak fluent English.
Women were identified for potential recruitment using purposive sampling. 
This meant that a broad range of women with differing characteristics were 
recruited in order to maximise the information gleaned in relation to the follow 
up process. In addition to the different types of follow up, women with a wide 
age range, range of disease stage, length of time from diagnosis and different 
treatment modalities were invited to participate, since these factors were 
identified as potentially affecting their needs and views of follow up.
The study was undertaken using semi-structured interviews, with an interview 
schedule, which was amended as required during the course of the 
interviews. All interviews were conducted by the same researcher (not the
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author). The interviewer was Dr Karen Roberts PhD, BSc (Hons), DPSN, 
RGN, who has extensive training and experience in qualitative methodology 
and the undertaking of interviews in qualitative research. She is nurse 
consultant in Gynaecological Oncology, Gateshead Health NHS Trust / 
Honorary Lecturer in the School of Health, Community & Education Studies at 
Northumbria University.
Consent to interview was sought from the respondent in an informal meeting 
prior to the interview. This appeared to set the scene for the interview and 
prepare and reassure the respondent of the general areas for discussion. The 
respondent also consented to the researcher contacting them following an 
interview if it was necessary to seek clarification of any part of the transcript. 
The consent to tape each interview was sought and the tapes that were used 
lasted for 90 minutes in a tape recorder with the facility for automatic tape 
reversal, therefore minimising the need to change tapes during the interview.
The interview could take place either in a clinic area at the hospital or at the 
woman’s home, according to her preference. The presence of a friend or 
relative was permitted if the woman so wished. Interviews were taped and 
transcribed by clerical staff, who did not have access to information on the 
identity of the participant. Field notes were made immediately after each 
interview. The field notes contained reflections on the context and non-verbal 
behaviour that had taken place during the interviews. The transcript data was 
analysed following each interview by both researchers and this directed the 
researchers as to which research subject was most able to illuminate the 
categories and themes as they developed. This enabled constant comparison 
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of events, and this process was continuously shaped by subsequent data 
collection78.
The data transcripts were then coded and analysed by the two main 
researchers (the interviewer and the author).
Ethical approval was granted by the local ethics committee.
Quantitative Study
A questionnaire was developed and piloted in the gynae oncology outpatients’ 
clinic. Questions were developed around themes and issues identified in 
previous qualitative20 and quantitative11 work in gynaecological oncology. 1 1  
questions (3 pages) covered basic epidemiological data, reports of their 
existing follow up, views on follow up visits, views on the role of nurse 
practitioners and on the reasons for follow up (appendix 3.4). The 
questionnaire was reviewed by members of the gynaecological oncology team 
and the views of patient groups were sought. It was amended accordingly and 
distributed to 104 consecutive patients attending for a routine follow up visit 
after treatment for a gynaecological malignancy, over a six-week period. 
Questionnaires were given out by clerks on arrival to the department and 
collected in a box within the waiting area. All questionnaires were completed 
anonymously. Clinical staff had no direct contact with patients during the 
process of them filling in the questionnaire in order to minimise bias.
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All women attending follow up after treatment for a gynaecological cancer 
were eligible to participate. Women with any or all treatment modalities 
(surgery, radiotherapy or chemotherapy) were included.
Data were analysed using the Statistical Package for the Social Sciences, 
version 1 2 ,0 .
Both studies were undertaken on women attending for follow up at the 
Northern Gynaecological Oncology Centre at the Queen Elizabeth Hospital, 
Gateshead, which is a tertiary referral Gynae oncology centre providing care 
for a population of just over two million people in the North East and North 
West of England.
Analysis of interviews
The aim of data analysis of the interviews was to generate theory that is 
completely grounded in the reality of the social world. This is achieved by 
constant comparison of the data and refining theoretical constructs through 
comparison with new data derived from the ongoing interviews79. Data were 
treated as referring to and representing phenomena (e.g. feelings, 
perceptions, experiences) rather than. As such the researchers were 
concerned with capturing and interpreting common sense, substantive 
meaning in the data.
Women were selected for interview in order to derive data according to the 
grounded theory principles of theoretical sampling.
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The interview transcript and the tape were stored together to facilitate open 
coding, and to enable subsequent revisits to the data for cross-referencing 
and comparison of data. The respondent number that had been allocated 
remained with the interview transcript, post-contact notes and tape. This 
assisted with the filing and comparative content analysis between the women 
and also between the different data sets relating to the same woman.
When reading and coding the interview transcripts line by line, the interview 
tape was listened to at the same time. This way, 'life' was returned to the 
transcript, and pauses, emotions and sarcasm was evident to the researchers. 
Therefore, although the words were transcribed Verbatim’, without any 
grammatical tidying, the transcripts were later refined with the non-verbal 
inferences included. The field notes were also reviewed at this time.
Data was initially coded independently, by both researchers, by hand. 
Computer analysis software was not used for two reasons. Firstly there were 
only a small number of interviews so the data was manageable by hand. 
Secondly there is a risk with the use of qualitative data software for analysis 
that the process of coding becomes automated and the meaning and sense of 
the data is lost. A cross-sectional analysis ‘code and retrieve’ method80 was 
used. A common system of codes was developed that were then applied 
(manually) to the data. This then allowed chunks of related data from different 
interviews to be looked at together. The chunks of data were then organised 
and summarised on a white board display and sorted in diagrammatic form to 
spot connections and inter-relationships81.
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This enabled the codes to be drawn together in order to develop categories. 
Analysis of the data led to the development of ideas or concepts, which were 
then linked in order to develop the narrative. In this way, the results narrative 
were grounded in the data. The aim was to develop theoretical, albeit 
emergent, concepts from the data from an early stage of analysis82 (Strauss 
and Corbin 1998). Outlying data, where discovered, were cross-checked with 
the themes developed in order to challenge the hypotheses that had been 
developed.
The analytic process involved data management (review, labelling, sorting 
and synthesising the raw data) descriptive accounts (making use of the sorted 
data to identify key phenomena and develop classifications) and explanatory 
accounts (building explanations and concepts to explain the data)83.
Results 
Qualitative Study
Seven interviews were carried out. Despite minor modifications to the 
interview schedule no additional concepts or themes were identified in 
interviews six and seven and therefore data saturation was regarded as 
having been achieved. Analysis was undertaken by both researchers. The 
audio tapes were listened to, field notes were reviewed and transcripts coded 
within a data management framework as described above. As major concepts 
and constructs were formed, the categories were collapsed together to form
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meaning. Working hypotheses were developed and these were then checked 
against the data.
Table 3.1 -  interview participants’ demographics
Respondent Age Stage Type of 
follow up
Time from
diagnosis
(months)
Recurrence
1 49 1C routine 44 No
2 55 1A Routine 19 No
3 60 1C Routine 6 No
4 76 2C routine 70 No
5 77 3C 0V05 81 No
6 67 1C Trifid s/routi ne 53 Yes
7 76 2C 0V05 81 No
Only one patient was identified and participated who had previously 
participated in nurse-led telephone follow up, so it was not possible to 
corroborate responses in relation to this type of follow-up. This was due to the 
premature closure of the TRIFIDS trial (with small numbers of participants and
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brief or no usage of nurse-based telephone follow up) and the subsequent 
demise of many of the participants.
One woman (respondent 6 ) chose to have her husband present and involved 
in the interview. All other women were interviewed on their own.
The participants had a range of disease stages, from stage 1A to stage 3C. 
They ranged from being six to 81 months after the completion of treatment.
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Figure 3.1 Codes, themes and concepts
Codes
Anxiety from blood test 
Anxiety from visit 
Fear
Reassurance from visit 
Reassurance from blood test result 
Attachment to team 
Personnel in clinic 
Temporality 
Resistance to discharge 
Multiple follow up 
Recurrence 
Access 
Inconvenience
Themes
Anxiety
Reassurance 
Blood test
Ignorance
Relationship with hospital 
team
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Concepts
Indoctrination 
Emotional roller coaster 
Addiction to follow up 
False expectations
Emotional experiences surrounding the follow up visit
Faced with a diagnosis of cancer, most people react initially with numbed 
shock and disbelief followed by anxiety, anger and depression84. In the 
context of this study, the interviews clearly demonstrated that women 
experience powerful emotions in their survivorship with heightened affect in 
the run up to, and aftermath of follow up visits. Many of the women reported 
negative thoughts and feelings prior to attending follow up appointments.
When it was time to come to the appointment I felt funny and scared. 
(respondent 4)
Going to the hospital makes me feel a little bit anxious, (respondent 3)
These feelings seemed to be related to the fear of detection of recurrence.
I wouldn’t say I was anxious even (before the visit). It’s like I think more 
about it; I think about what could happen, (respondent 7)
I just hope that everything is going to be alright, (respondent 4)
The source of a patient’s distress is often focused upon the reality of their 
diagnosis, what it means to them, and how they now appraise their future.
The women also reported gaining a lot of positive feelings afterwards from 
having attended the follow up visits. In particular many of them describe 
reassurance and a feeling of confidence that they derive from attending.
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I feel great when I go out... I just feel safe and it gives me confidence, 
that’s the word really: confidence, (respondent 7)
It makes me feel confident that everything is alright and that I haven’t 
got any cancer coming back, (respondent 5)
It gives me confidence that all is well or if  anything is wrong they will 
spot it. (respondent 5).
One woman who was interviewed had tried nurse-led telephone follow up, and 
did not get the same reassurance from it:
There’s always that thing deep down in your mind that you’re not right 
and on the telephone they don’t know. I’m the one to say ‘oh yes, I’m all right’ 
even i f l ’m not....I would rather have come to clinic, (respondent 6 )
For these women who are already in an established follow up scheme it would 
seem that they become psychologically reliant on the follow up for 
reassurance that they remain free of disease. They seem to experience 
powerful emotions around the time of their visits, with a sense of elation and 
relief afterwards due to the confirmation of their disease status. This may 
contribute to positive reinforcement of the benefits of follow up.
Fear of recurrence
The women interviewed all expressed concerns regarding recurrence of their 
disease.
I suppose it’s something that can come back (respondent 3)
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I do think about it coming back; you can’t say it would never come 
back, (respondent 2 )
When you get your aches and pains and something different, you’re 
thinking straight away ‘Is the cancer back?’ (respondent 6 )
Although there was some evidence of unrealistic expectations of what 
detection of recurrence at the clinic would deliver:
They always say early detection is better, isn’t it? (respondent 3) 
Understanding of follow up and investigations
For most women, the positive emotional experiences seemed to stem from 
what they regarded as being the primary reason for follow up: ensuring that 
there was no recurrence. Most of them were having regular CA125 blood tests 
(a tumour marker for ovarian cancer), and they rested a lot of importance on 
the blood test.
Well I suppose they wouldn’t do it if it wasn’t important, and they can 
tell if  there’s any cancer cells there, (respondent 4)
The bloods, that to me is important As soon as I know it’s rising -  I 
know there is something wrong, (respondent 6  -  previously had a recurrence)
I think they rely on the blood test So when I don’t get a letter or a 
telephone call, I start to feel safe again and that everything is all right 
(respondent 7)
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This may come from an iatrogenic introduction of reliance on CA125 
measurements, especially for those women who undergo chemotherapy. 
These women have CA125 measurements after each cycle of chemotherapy 
to contribute to determining response to treatment. Many women therefore, for 
understandable reasons, become preoccupied with this measurement and its 
meaning with regards to their ongoing well being. The withdrawal of this at the 
end of treatment is in keeping with the withdrawal of all other forms of support, 
other than routine clinics at this point in time.
Temporal Changes
Perspectives on follow up seemed to change over time. Confidence was again 
a key theme, and the need to develop confidence after such a difficult 
diagnosis and treatment. Confidence for these women seemed to be bred by 
attendance at the cancer centre:
I prefer to come here (cancer centre) (respondent 7, 70 months from 
diagnosis)
They offered to transfer me back to (the unit) but I didn’t want that I ’d 
rather travel to (the centre); I ’m happy there, (respondent 2)
In some cases this may have been due to experiences earlier on in their care 
pathway, or possibly because of the requirement for referral to the centre to 
gain the type of care they needed:
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I am really glad that I am seen at (the centre) because I found the (unit) 
totally useless, (respondent 5)
Confidence may also be bred by seeing a member of medical staff rather than 
nursing staff:
I think I would rather see a doctor; nothing against nurses -  I could not 
fault the care I have had here, (respondent 7)
I prefer to have a doctor, but I don’t mind seeing the nurse.
Although this view was not universal, and some women were happy to see 
either a doctor or a nurse. However this is a view that may alter with time, 
possibly as the women become more confident:
Maybe at first, when you are more apprehensive (you want to see a 
doctor) but as time went on I didn’t mind who I saw. (respondent 4)
This may be linked with increased confidence that, as time progresses, the 
cancer is less likely to recur:
The longer it gets, the better the chance I’ve got. (respondent 7, 70 
months from diagnosis)
Quantity of follow up
For many of the women interviewed, they would like to be seen as often as 
possible, and for as long as possible:
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She would come here every week, as long as we get good news every 
time!! (husband of respondent 6 )
(I would come) as much as you like. I would come all o f the time. I 
mean I wouldn’t put a time on it, say ten years, or even fifteen years. I would 
come every six months, or at worst every year. I would hate (discharge). To 
me that’s my safeguard (respondent 7)
One woman was even having follow up at the centre and also at the unit:
They do more or less the same (at the centre and unit). They just 
examine me ..and then sometimes do the blood test, (respondent 4, who was 
still having follow up in the unit despite having been discharged by the centre)
Although for some, they came because they felt they had to and needed to, 
rather than because they found it personally beneficial:
The least I have to go the better. It is necessary...! am happy to go 
every three months and let them see how I am. ...It could be away for a long 
time, but there is a chance it might come back. I ’ve just got to keep getting 
followed up really, (respondent 3)
Quantitative Study
96 women replied to the questionnaire, and all questionnaires were used for 
analysis.
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Table 3.2 Epidemiological information
N (n=96) %
Cancer site:
Ovary 31 32
Corpus 14 14
Cervix 23 24
Vulva 9 9
Vagina 1 1
Missing 18 19
Treatment:
Surgery 90 94
Chemotherapy 2 2 23
Radiotherapy 7 7
Missing 1 1
Follow up frequency (months):
3 37 39
4 1 1
6 29 30
1 2 26 27
missing 3 3
85/93 women (91%) thought that the current frequency of their follow up was 
just right. 2 women thought they were being seen too often. One was a 33 
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year old woman who was on three monthly follow up after surgery for 
carcinoma of cervix and who was 26 months since diagnosis. The other was a 
59 year old woman on six monthly follow up who had had surgery and 
chemotherapy for carcinoma of the ovary and was 73 months post diagnosis. 
5 women thought they were not being seen often enough (table 2).
Table 3.3 Women who thought their follow up was not often enough
Case Age
(years)
Cancer
site
Treatment(s) Follow up 
frequency
Time since 
diagnosis
11 59 Ovary Surgery,
chemotherapy
1 2 57
26 58 Cervix Chemoradiotherapy 3 Unknown
32 64 Corpus Surgery 1 2 61
33 37 Cervix Surgery 6 150
34 36 Cervix Surgery 6 4 4
82/92 (89%) of women thought that a hospital doctor should provide their 
follow up. Only 22/92 (24%) thought follow up should be by a specialist nurse 
and 6/92 (7%) thought it should be by a General Practitioner (p<0.001, 
multiple answers permitted). There was no difference between those who had
58
been in follow up for less than five years (n = 62) and those who had been in 
follow up for more than five years (n=30),
58/90 (64%) of women reported having a consultation and being examined 
during their clinic visit. A further 27/90 (30%) of women reported having a 
blood test in addition to the consultation and examination. 2/90 (2%) reported 
having a consultation and a blood test, but no examination. Women who had 
been treated for ovarian cancer were more likely to report having blood tests 
done (22/28) than those who had been treated for cancer in other sites (4/47) 
(p<0.0001). When asked to rank the components of the visit according to their 
importance (consultation, examination or blood test), women ranked 
examination as the most important, followed by the consultation then the 
blood test (p<0.0001). However, those women who reported having regular 
blood tests were much more likely to regard the blood test as being more 
important than the examination (16/29 (16%) versus 3/61 (84%), p <0.0001). 
The consultation was relatively less important to women who had been in 
follow up for more than five years (p=0.01). Women with ovarian cancer 
thought that the blood test was relatively more important, whereas women 
who were being followed up for other cancer sites thought the examination 
was more important (p=0 .0 0 1 ).
6 / 8 6  (7%) reported always seeing the same doctor for follow up, 56/86 (65%) 
reported sometimes seeing the same doctor and 24/86 (25%) reported never 
seeing the same doctor. 21/85 (25%) of women reported seeing a specialist 
nurse when they attended for follow up. 7/20 women who reported seeing a 
specialist nurse in the follow up clinic thought they should be followed up by a 
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specialist nurse, whereas 13/49 women who did not see a specialist nurse 
thought that they should (p = not significant).
48/89 (54%) of women reported feeling more anxious than usual prior to 
attending for the routine follow up visit, whereas only 2/89 (2%) reported being 
less anxious. However after the follow up visit 9/90 (10%) still reported feeling 
more anxious than usual but 34/90 (38%) reported feeling less anxious than 
usual (p<0.0001, Wilcoxon signed rank test).
Women were asked to complete a five point Likert scale (strongly agree, 
agree, neither agree nor disagree, disagree, strongly disagree) on the role of 
the specialist nurse in the clinic. They ranked four statements: listen to
concerns, answer questions, take blood and detect signs of disease recurring. 
Frequencies are presented in table 3. Women ranked listening to concerns 
and taking blood as the most important roles for the specialist nurse. They 
viewed detecting recurrence as significantly less important for nurses, when 
compared to their other functions within a follow up clinic (mean ranks 
compared, p<0 .0 0 0 1 ).
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Table 3.4. Responses to the question ‘What do you think the nurse}s 
role is?’
(percentages in brackets)
Strongly
agree
Agree Neither agree/ 
disagree
Disagree Strongly
disagree
Mean rank
(p<0 .0 0 0 1 )
Listen to 
concerns
31/80 (39) 36/80 (45) 11/80(14) 2/80 (3) 0/80 (0 ) 2.30
Answer
questions
25/80 (31) 39/80 (49) 15/80(19) 1/80(1) 0/80 (0 ) 2.47
Take blood 29/78 (37) 34/78 (44) 15/78(19) 0/78 (0) 0/78 (0) 2.36
Detect signs 
of disease 
recurring
27/80 (34) 20/80 (25) 22/80 (27) 9/80(11) 2/80 (3) 2.87
Finally women were asked to rank six statements about follow up in order of 
their importance (Table 4). They assigned numbers 1-6 to the statements, 
where 1 was the most important and 6  was the least important. The mean 
ranking for each statement was calculated and the rankings were compared 
using the Friedman test. Women ranked detection of recurrence as the most
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important reason for attending for follow up (p<0.0001). They placed very little 
value on the collection of data as a rationale for follow up.
Table 3.5 'Which of the following reasons for coming for follow up is 
most important to you?’
(ranked 1 -  6 , 1 =most important, 6 =least important).
Mean rank
(p<0.0001)
To detect if disease is coming back 1.40
To check recovery from treatment 3.01
To treat and symptoms 3.39
To talk about concerns 3.82
To treat any side effects of treatment 4.16
So that the hospital can collect information about recovery from cancer 5.22
Views of Women in Follow up for More than Five Years
Detection of recurrence remained the most important reason for follow up, 
even in those women who had been in follow up for more than five years, and 
they felt it should be by a hospital doctor. However, women who had been in 
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follow up for more than five years thought that checking recovery from 
treatment was more important than those with a shorter duration of follow up 
(chi squared, p=0.004). This group also placed a higher emphasis on the 
importance of the consultation than those women who had been in follow up 
for less than 5 years (chi squared, p=0.004). However, even after 5 years of 
attending, these women reported similar levels of anxiety around the follow up 
visit to those women who had been in follow up for a shorter period.
Discussion
The qualitative interviews demonstrate, for the first time, the views of women 
undergoing follow up after both early stage and advanced ovarian cancer. 
Robust qualitative methodology has been used in order to produce valid data 
and analysis. However, qualitative research can only be generalised through 
the generation of theoretical statements which then need to be tested by 
application in other contexts85. That said, the degree of concordance across 
the interviews is quite striking. This resulted in data saturation after only seven 
interviews, compared to the expected ten interviews. The quantitative study 
presented provides triangulation63 and confirms that these views of follow up 
are more widely held54.
Grounded theory was developed as a means to enable qualitative researchers 
to respond to the belief held by many positivist (or quantitative) researchers 
that qualitative research was unscientific because it rejected controlled 
experiments and appeared to accept individual interpretation86,87. Therefore,
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the development of grounded theory procedures, which include a set of rigidly 
systematic steps for sampling, data collection and analysis were developed by 
Glaser and Strauss86. This paper has used these methods to develop the 
narrative around women’s expressed experiences of follow up.
One aspect of this is the collection of ‘field notes’ after the interview. In 
practice, field notes might fail to capture reflections upon the environment of 
data collection and that this may have an impact upon the subsequent 
analysis. Schatzman and Strauss78 describe the need to develop different 
records of the same incident, which allows multiple recording of data that 
supports effective cross referencing, but also embeds within the field notes a 
foundation for data analysis. This ensures the movement of data beyond 
simple story telling.
The group that were interviewed were deliberately diverse in terms of their 
stage of disease and length of time in follow up (purposive sampling)63. 
Despite this they reported very similar experiences of the follow up process, 
which may indicate that such experiences are widespread. The group is 
biased by the fact that they are all women who, by definition, are complying 
with follow up and it would be interesting to be able to interview women who 
choose not to attend for follow up about their reasons for this. This, however, 
would be challenging to achieve as such women are no longer under the 
hospital’s care and may be reluctant to consent to taking part. Furthermore 
this was outside the scope of this project.
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Both parts of this chapter have shown that women think that detection of 
recurrence is the main reason for attending for follow up. This is coupled with 
some unrealistic expectations in terms of the likely impact on survival of the 
early detection of any recurrence. They derive both positive and negative 
emotional experiences from being reviewed. However the single biggest 
benefit identified is a feeling of reassurance and safety. This outweighs any 
negative views of the process.
The findings of this study are in keeping with a previous qualitative interview 
study conducted by Bradley et al, but that study was limited to women who 
had completed treatment for all gynaecological cancers, which had been 
found to be early stage20. Our paper supports the idea that the anxieties and 
reassurance achieved by attending for follow up is present in women with 
diverse stages of ovarian cancer and therefore with very variable prognoses. 
Even for those women with advanced stage disease, which is highly likely to 
prove terminal, the reassurance still seems to exist.
Some women would clearly like to be followed up as often as possible and for 
as long as possible, despite a lack of evidence to show any benefit from such 
a practice. This is at odds with moves to shift from a clinically led approach to 
follow up care to supported self-management88.
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Conclusions
Women report positive experiences from routine follow up. Despite some 
feelings of anxiety prior to the visit, confidence is gained from the reassurance 
that their disease has not returned. Therefore any move to reduce the length 
and frequency of routine follow up care, or to introduce nurse-based follow up, 
may meet with resistance from women, especially those already established 
in a follow up programme. This study has demonstrated that it would be 
important for any randomised trial comparing different sorts of follow up to 
address issues around reassurance and confidence for women who have 
completed treatment for gynaecological cancer. Failure to do so could 
potentially prevent women from consenting to randomisation in a trial since 
they would otherwise receive current standard practice of routine follow up.
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Appendix 3.1 Interview Schedule for Follow up Interviews
• Introduction to research project
• Get consent form
1. Why do you think you are being followed up?
o  How does that feel?
o  What is the benefit of early detection of recurrence? 
o  What do you think is the risk of the disease recurring? 
o  How would you feel if that happened?
2. What are the benefits and drawbacks of being followed up?
o  For different types of follow up (previous trial patients)
3. How do you find the appointment itself?
o  How do you feel before you come? 
o  Who, where and when would you wish to be followed up? 
o  What is the most important part of the follow up visit for you? 
o  How do you feel about the blood test and its results? 
o  Any practical problems with follow up appointments? 
o  How do you feel afterwards?
4. Do you worry about recurrence between visits?
o  If worried, what would you do?
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Appendix 3.2 -  Consent Form
Qualitative Study of Follow up after Ovarian Cancer
Name of Researchers: Miss FM Kew, Sr JA Guest
Please read carefully and tick box as appropriate:
I | □ I confirm that I have read and understood the information sheet for the above
study and have had sufficient time to consider my participation.
□ a I understand that my participation is voluntary and that I am free to withdraw at any time without giving reason or affecting my medical care.
| | □ I understand that staff involved in the research may examine my medical
records for the purpose of checking the information recorded.
1 1 □ I understand that any documentation relating to me will not identify me by
name and will be kept confidential.
I | □ I agree that my General Practitioner may be told that I am taking part in this
study.
Patient’s Name
Signature............................................  Date,
I (the Investigator/Doctor in charge), confirm that I have explained to and fully 
discussed with the patient the nature, purpose and likely effects of this study.
Doctor’s Name
Signature Date
Appendix 3.3 -  Patient Information Text
The Northern Gynaecological Oncology Centre at the Queen Elizabeth Hospital in 
Gateshead is currently looking at the experiences women have in relation to their 
follow up care following treatment for ovarian cancer.
At present there are many different kinds of follow up and we need to understand 
what is important to women in their follow up care.
What does the study entail?
If you agree to take part in the study, your name will be passed on to our 
Researchers, Fiona Kew and Alison Guest. Fiona is a Senior Registrar and Alison is 
a Macmillan Clinical Nurse Specialist based at Queen Elizabeth Hospital, Gateshead. 
They will organise a trained interviewer to talk to you for about one hour about your 
experiences of follow up. This can be done at the hospital or at home, which ever you 
prefer. The discussion will be recorded so that we can refer back to it. Anything you 
say will be anonymous and will not have any effect on your care.
Anticipated benefits of the study:
Participation in this study may not benefit you directly. However, we have often found 
that being offered the opportunity to talk about your experience can be helpful. We 
are hoping that any issues or problem areas that are discussed will help the medical 
and nursing teams to develop interventions in these areas, it will also serve us well 
in developing our future research programmes, and help us to ensure that we are 
asking the right questions that are relevant to patient care.
If any issues are raised that you as an individual wish to discuss further then we will 
arrange for you to see and speak to someone who can help you.
Thank you for taking time to read this information sheet.
For Further information, please contact: 
Miss FM Kew—Senior Registrar 
(0191)482 0000
Alison Guest—Modern Matron 
(0191) 482 0000 Bleep 2344
Secretary: (0191) 445 6148
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Appendix 3.4 Questionnaire Gateshead Health
NHS Foundation Trust
NHS
Northern Gynaecological Oncology Centre 
Queen Elizabeth Hospital, Gateshead
PATIENT QUESTIONNAIRE
Age:......................................... ...............
Marital Status:......................... ...................................................................................
Type of Cancer....................... ...................................................................................
Date of Diagnosis: Month:...........................  Year: ...............
Type of treatment: (tick all that apply)
□  Surgery □  Chemotherapy □  Radiotherapy
(drug treatment) (x-ray treatment)
□Other:.....................................................................................................................
PLEASE TICK ✓ ALL THAT APPLY TO YOU
Yes No
1. Has your cancer returned since your original treatment? □ □
If yes, have you had further treatment? □ □
2. How often do you come for follow-up at the hospital?
□  Every 3 months □  Every 6 months
□  Every year □  Other / state:.................
Do you think this is:
□  Just right □  Too often □  Not enough
If not right, how often would you like to be seen? ...................
Please turn the page
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3 a. Who do you think should do your follow-up? (please tick all that apply)
□  Hospital doctor
□  Specialist nurse
□  General practitioner
□Other, please specify......................................................................................
4a. When you visit the doctor at the hospital what happens? (please tick ONE)
□  Chat and examination (internal and tummy)
□  Chat, examination and blood test
□  Chat and blood test
□Other(Pleasestate):.......................................................................................
5. When you visit the hospital, do you see the same doctor?
□  Always □  Sometimes □  Never
6. Before you come to the hospital do you feel:
□  More anxious than usual
□  Same as usual
□  Less anxious than usual
6a. After you have been to the hospital do you feel:
□  More anxious than usual
□  Same as usual
□  Less anxious than usual
7. Which part of your appointment do you feel is most important?
□  Chat □  Blood test □  Examination □  Other: ...
W h y ? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8. When you come for your appointment do you usually see a specialist nurse?
□  Yes □  No
9. When you visit the hospital, do you see the same nurse?
□  Always □  Sometimes □  Never
What do you think the nurse’s role is? (Please ^  one for each statement)
Listen to concerns:
□Strongly agree □  Agree □Neither agree/disagree □Disagree □  Strongly disagree
Answer questions:
□Strongly agree □Agree □Neither agree/disagree □Disagree □  Strongly disagree
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Take blood:
□Strongly agree □  Agree □Neither agree/disagree □Disagree □Strongly disagree
Detect signs of disease recurring 
□Strongly agree □  Agree □Neither agree/disagree □Disagree □Strongly disagree
Which of the following reasons for coming for follow up is most important to you? 
(Please put in order of importance, where 1 is most important and 6 is least 
important).
  To check recovery from treatment
  To treat any side effects of treatment
  To talk about concerns
  To detect if disease is coming back
  To treat any symptoms
  So that the hospital can collect information about recovery from cancer
Other:..................................................................................................................
We would welcome any comments your hospital appointments.
Please return the questionnaire in the box provided in the waiting room. 
Thank you for taking time to complete this questionnaire.
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Chapter 4 -  Feasibility Study
Introduction
As discussed, the routine follow up of patients after treatment for cancer is 
standard practice. It is done on the assumption that picking up recurrent 
cancer before symptoms develop will permit earlier treatment and therefore 
better survival rates rather than waiting for a patient to develop symptoms. It 
is also assumed that these visits are reassuring for the patients. However, 
there is a lack of evidence to support this practice in gynaecological cancers, 
and no randomised trials have been performed.
In order to determine the feasibility of a randomised controlled trial, and to 
assist with power calculations for the trial, a pilot randomised controlled trial 
was designed. Trial information and consent forms were developed 
(appendices 4.1 and 4.2) and ethical approval was granted by the South Tees 
Local Ethics Committee. No funding was secured so the study was run within 
existing resources.
Method
The study was designed to assess feasibility for a pragmatic randomised- 
controlled trial comparing routine hospital follow-up appointments with a 
system of patient-initiated follow up. Blinding of participants or clinicians was 
clearly not feasible. The primary outcome of the main trial was to be survival.
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The feasibility study was run in the Gynaecological Oncology Cancer Centre 
in the James Cook University Hospital in Middlesbrough. This cancer centre 
provided care for the Teesside Cancer Care Alliance, which was responsible 
for the provision of care for a population of just over 1,000,000 people. Ethical 
approval was granted by the South Tees Ethics Committee.
Inclusion Criteria
All patients who had completed first-line treatment for a histologically 
confirmed gynaecological cancer, regardless of stage or site, were potentially 
eligible for recruitment.
Exclusion Criteria
• Women who needed ongoing review for problematic symptoms or side 
effects
• Women who were under follow-up for a previous malignancy
• Women who were enrolled in another trial that required follow up. 
Randomisation and Stratification
Randomisation was performed by the University of York Telephone 
Randomisation service based in the Department of Health Sciences. This 
service provided locations across the United Kingdom with immediate and 
unbiased allocation of patients to treatments through the use of a freephone 
telephone number and appropriate bespoke computer software. 
Randomisation was stratified into two groups based on the natural histories of
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the different cancer sites. For the feasibility study, there was a 2:1 ratio 
randomisation for patient initiated follow up versus standard follow up. This 
was in order to provide maximum information on any issues relating to the 
feasibility of administering patient-initiated follow up. All consenting eligible 
patients were randomised to either 'patient-initiated follow-up' or 'standard 
follow-up'. Randomisation was stratified by cancer type (ovary, fallopian tube, 
primary peritoneal versus endometrium, cervix, vagina, vulva) and disease 
status (disease free versus residual disease) to ensure that these variables 
were evenly distributed across the two groups of patients. The stratification is 
based on the premise that that there are no curative salvage treatments for 
the first group, whereas there are (in some cases) for the second group.
Outcome Measures
Disease specific and overall survival were planned to be the primary outcome 
measures in the main trial. Rates of recurrence were not collected as it was 
thought to be an unreliable surrogate marker for survival, in view of potential 
length time bias in the detection of recurrence in the routine follow up arm. 
Planned secondary outcome measures for the main trial were quality of life, 
anxiety and depression scores, cost effectiveness, rates of surgical and 
medical intervention in primary and secondary care and patient acceptability. 
However cost effectiveness calculations and attempts to collect information on 
rates of intervention, patient acceptability and clinic use in the routine follow 
up were not undertaken in the feasibility study due to lack of funding. In order 
to assess feasibility, within this study data was collected on recruitment rates 
amongst eligible patients, ability to complete quality of life, anxiety and 
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depression scores at baseline, 6  and 1 2  months, use of clinic appointments 
and use of the telephone line in the patient initiated group. Data collection of 
quality of life, anxiety and depression scores was not feasible beyond twelve 
months due to the lack of funding.
Quality of life and patient acceptability data was collected using standardised 
questionnaires using EQ-5D, SF-36 and condition-specific measures 
(EORTOC QLQ C30 and OV24). Anxiety and depression was measured 
using the Hospital Anxiety and Depression scale. Questionnaires were 
administered at randomisation, after six months and after twelve months.
A sample size calculation was not performed since the outcome measures 
were based around feasibility.
Feasibility Study Protocol
Standard follow up was determined as being the model of care recommended 
in the Teesside Cancer Care Alliance Gynaecological Oncology guidelines at 
the time. An intervention arm of patient initiated follow up was developed 
based on previous work in women who had completed treatment for breast 
cancer58,89. All potentially eligible women were seen in out patients’ clinic eight 
weeks after completion of treatment. All women who agreed to participate in 
the trial completed baseline quality of life questionnaires (SF36, EQ5D, 
EORTOC QLQ-C30 and OV24, Hospital Anxiety and Depression scales).
Standard Follow-up Arm Protocol
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Women randomised to standard follow up were given appointments for 
outpatient clinics according to the following schedule:
• Year 1 3 monthly visits
• Year 2 4 monthly visits
• Year 3 6  monthly visits
• Year 4 annual visit
• Year 5 annual visit, then discharge
At each visit the woman were seen by medical staff (consultant or specialist 
registrar), with or without the presence of specialist nursing staff, according to 
standard local practice. A relevant history was taken and a clinical 
examination undertaken. Investigations were not performed routinely (as was 
standard practice), and were only performed when clinically indicated.
Interval visits could be arranged according to clinical need, as determined by 
hospital medical staff, nurse specialist or the General Practitioner.
Patient-initiated Follow up Arm
Women randomised to patient-initiated follow up participated in a semi­
structured interview with a gynaecological oncology specialist nurse. This was 
undertaken shortly after randomisation. They were given advice about how to 
contact the service and then no further routine appointments were arranged.
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Semi-structured interview
The interview was structured around the following areas:
• what is patient initiated follow up
• when to contact the hospital
• when to contact the General Practitioner rather than the hospital
• how to contact the hospital
• what will happen when the woman telephones the help line
• any other issues the woman wishes to discuss
Each patient was given a patient-information leaflet (an example is given in 
appendix 4.3), which gives details of symptoms that may cause concern, 
when they should contact the hospital and how to access the service. Four 
different leaflets were developed, each of which was specific to one cancer 
type. All leaflets were reviewed and approved by the trust’s 'Patient 
Information Group’.
Telephone Help Line
The telephone help line was a confidential service, which participants were 
encouraged to use if they develop worrying symptoms. The telephone line 
was manned at defined times by Nurse Specialists (specified in the patient 
information leaflet), and a confidential answer phone was available at all other 
times. Women were guaranteed a return call within two working days of any
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message and a clinic appointment, if appropriate, within five working days. 
General Practitioners were also able to access the system through this route if 
they wished, or through the traditional route via the consultants’ secretaries.
Arrangement of Clinic Appointments
Clinic appointments were arranged if the woman complained of the following 
symptoms:
• Any new lumps or masses in her abdomen
• Bleeding from the vagina
• Bleeding after sexual intercourse
• Weight loss, without being on a diet or exercising
• Haematuria
• Lump in her neck
Clinic appointments were arranged if the patient complained of the following 
symptoms, lasting for more than 3 days:
• Pain in the abdomen or pelvis, that was not present previously
• Bloating or abdominal swelling
• Feeling generally unwell
• Nausea and vomiting
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• Diarrhoea (new -  no obvious cause)
• Bleeding from the rectum
• Constipation (new -  no obvious cause)
• Urinary frequency
For other symptoms the patient was advised to contact their General 
Practitioner. Appointments could be made out with these recommendations at 
the discretion of the clinical team.
Results
72/225 (32%) of eligible women were recruited between September 2001 and 
July 2003. Recruitment was halted after 23 months because sufficient 
information had been gleaned to support a grant application. 48/72 (67%) of 
women were randomised to patient initiated follow up and 24/72 (33%) were 
randomised to routine follow up. 29/72 women had completed treatment for 
ovarian/fallopian tube/primary peritoneal cancer, of whom 9 were randomised 
to routine follow up and 2 0  were randomised to patient initiated follow up. 
43/72 women had been treated for uterine/cervical/vulval cancer, 15 were 
randomised to routine follow up and 28 to patient initiated follow up. All 
women were disease free at randomisation.
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Recruitment Flow Diagram
225 women approached
72/225 randomised (32%)
Disease free 72/72
Persistent disease 0/72
Ovary/fallopian tube/PPC 39/72 Uterine/cervix/vulva 43/72
Routine arm 9/72 Patient initiated 20/71 Routine arm Patient initiated 28/72
At September 2006, 6/24 (25%) women in the routine follow up arm and 11/48 
(23%) women in the patient initiated arm had died. 3 women were alive with 
disease in each arm. Disease status was not available for one woman in the
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patient initiated arm. 2/72 (3%) had withdrawn from the trial. As such the 
overall recurrence rate was 23/72 (32%).
Baseline quality of life and anxiety/depression questionnaires were completed 
by 71/72 (99%) women. 32/71 (45%) completed 6  month questionnaires and 
26/67 (39%) completed 12 month questionnaires. No significant differences 
were seen in quality of life or anxiety and depression at randomisation or at 
six months. However, this was a feasibility study and as such was not 
powered to detect a difference.
Over a four year period from the start of randomisation (01/09/2001 to 
01/09/2005), there were 37 telephone calls from 24 women within the patient 
initiated arm. 21/37 (57%) calls were made within 6  months of randomisation. 
5 women had clinic appointments made after consulting with their general 
practitioner, without contacting the help line. There were 82 clinic visits for 
women in the patient initiated follow up arm. The median length of follow up 
for this group was 35 months (range 26 -  46 months). Had they received 
routine follow up, they would have been expected to have a minimum of 392 
visits based on the routine follow up schedule.
Discussion
This feasibility study demonstrates that recruitment to a randomised controlled 
trial comparing patient initiated follow up with routine follow up in secondary or 
tertiary care clinics in women who have completed treatment for a 
gynaecological cancer is feasible. The recruitment rates, however, are lower
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than those demonstrated by Gulliford et a!58. They reported recruitment rates 
of 93% in women who had completed treatment for breast cancer, in a trial 
that compared standard follow-up with reduced-frequency follow-up. A lower 
rate of 66.5% is seen in Grunfeld’s paper, also in women who had completed 
treatment for breast cancer15. The intervention arm of this particular trial 
considers follow-up in General Practice rather than patient-initiated follow-up. 
However most of these patients were already in a scheme of hospital-based 
follow-up when approached which may explain the lower recruitment rates. In 
both of these studies women were still offered scheduled consultations, unlike 
in this study, and it is possible that this is one of the reasons that a higher 
proportion of women in our study declined randomisation. Lack of funding for 
the study may also have contributed to a failure to identify and approach all 
potentially eligible women. Ohlsson recruited 107 patients62, and Kjeldsen 
recruited 597 patients61 in people who had been treated for colorectal cancer 
but rates of recruitment are not available for these studies.
Data on the planned primary outcome measure for the main trial (survival) 
was readily available for all patients recruited to the feasibility study through 
the local gynaecological oncology database, which was populated through the 
multi-disciplinary meetings. There were no women for whom mortality data 
was not available. In a larger trial it is likely that some women would be lost to 
their local cancer centre, but mortality data should be available for all women 
via the cancer data registries using their NHS number.
All but one woman completed the quality of life and anxiety and depression 
measures at baseline. This suggests that completion of this large array of 
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measures is practicable for women who are motivated to be in the trial. The 
dramatic drop off in the numbers of questionnaires completed at 6  and 1 2  
months mostly reflects a failure to send out many of the questionnaires and a 
failure to send out the planned reminders due to lack of funding. It also 
highlights the need to address collection of this data, particularly from women 
in the patient-initiated arm, in the main trial.
The use of the telephone line did not result in an excessive workload. It also 
resulted in a notable decrease in the number of clinic reviews compared to 
that which would have been expected if the same group of women had been 
receiving routine follow up.
Brown et al carried out a trial of patient initiated follow up of breast cancer89. 
50 women were randomised between routine follow up and patient initiated 
follow up. Over the course of one year, only three telephone calls were made: 
one from the standard arm and two from the patient-initiated arm.
Gulliford et al similarly found that using patient initiated review between 
routine mammography visits did not result in an excessive use of the 
telephone line, when compared to women who were having standard follow 
up after treatment for breast cancer58.
This study clearly demonstrates that a randomised controlled trial of follow up 
after gynaecological malignancy is feasible. The feasibility study showed 
acceptable rates of recruitment and follow up. Rates of recruitment and 
research follow up are likely to be enhanced by having dedicated funding and 
staff time. Research follow up can be further enhanced by repeated postal
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and telephone reminders to women who have not returned their 
questionnaires and also with the use of web based questionnaires and data 
collection.
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Appendix 4.1 - trial information
South Tees Hospitals
N H S  T r u s t
The Role of Follow-up after Gynaecological Cancer 
Patient Information Leaflet
Introduction
You are being asked to take part in a research study. Before you decide, you need to 
understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and talk about it with friends, relatives and 
your GP (General Practitioner), if you wish. Ask us if there is anything that is not clear 
or if you would like to know more. Take time to decide whether or not you wish to 
take part.
Consumers for Ethics in Research (CERES) have a leaflet called ‘Medical Research 
and You’. This leaflet gives more information about medical research and looks at 
some questions you may want to ask. A copy may be obtained from CERES, PO Box 
1365, London N16 OBW.
Thank you for reading this leaflet.
What is the purpose of this study?
It is normal for patients to have follow up appointments in hospital clinics after 
treatment for cancer. It has always been thought that finding people whose cancer 
has returned (‘recurred’) at these visits would allow earlier treatment, and this would 
mean that they would, on average, live longer. However, research has shown that 
most people discover that their cancer has returned for themselves, in between their 
hospital visits, because they get symptoms. Research in breast and bowel cancers 
tell us that those people whose cancer is found again by a doctor in the clinic do not 
live longer, on average, than those people who find the cancer has returned for 
themselves.
The reason for doing this study is to compare routine follow-up appointments in 
hospital clinics with appointments that are given when you, the patient, asks for it 
(patient-initiated follow-up).
Why have I been chosen?
We are asking all our patients that have just finished treatment for cancer to take part 
in this trial. The only people that will not be asked are those that still have problems 
and so need to keep seeing us.
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Do I have to take part?
It is up to you whether or not to take part. If you do decide to take part, you will be 
given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to pull out of the trial at any time, and without 
giving a reason. This will not affect the standard of care you will receive.
What will happen to me if I take part?
Sometimes, because we do not know which way of treating patients is best, we need 
to compare two different ways of doing things. People will be put into groups and 
then compared. A computer, which has no information about the people involved, 
selects the groups -  i.e. by chance or ‘randomly’. Patients in each group then have a 
different type of follow-up and the two groups are compared.
You have a 2/3 chance of being allocated to patient initiated follow up, and a 1/3 
chance of being allocated to standard follow up. The research project will last for five 
years in total.
If you are chosen to have routine follow-up, you will see us in the clinic for five years. 
You will be seen every three months for the first year, every four months for the 
second year, every six months for the third year and then once a year until the end of 
the five years (two visits). After this you will be discharged. If you have any problems 
in between these visits you can get in touch with us, either through your General 
Practitioner (GP) or by telephoning the department, and we can bring the 
appointment forward if needed.
If you are chosen to have patient-initiated follow-up then it will be up to you when, or 
if, you are seen. We will give you information about your disease so that you know 
which symptoms to look for and when to call us. There is a special telephone line that 
is just for patients in this part of the trial. If you telephone us and we need to see you, 
we will see you within five working days of the call. You will also be asked to answer 
some questions about your health and general well-being after six months, then at 1 2  
months and then once each year, until five years have passed.
What are the possible risks and benefits of taking part?
We hope that both ways of looking after you will be of benefit. However there may be
some differences in the benefits from the two different types of follow-up. The 
information we collect from this trial will help us to know in future the best way of
following patients after they have been treated for cancer.
What happens when the research stops?
When the trial has finished, everybody will have the same type of follow-up. The trial 
will tell us which type of follow-up is best and therefore which type of follow up 
everybody will have.
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What if something goes wrong?
If you are harmed by taking part in this trial, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have 
grounds for a legal action but you may have to pay for it. Regardless of this, if you 
wish to complain about any aspect of the way you have been approached or treated 
during the course of the study, the normal National Health Service complaints 
processes are available to you.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you that leaves the hospital/surgery 
will have your name and address removed, so that you cannot be recognised from it.
Your General Practitioner (GP) will be told if you choose to take part in this trial.
What will happen to the results of the research study?
When the study is finished, the results will be published in one of the medical 
journals. The results will also be presented at medical meetings. You will not be 
identified in any way in any such article or at any such meeting.
Who is organising and funding the research?
This study is a pilot study and is being funded by the Gynae Oncology Unit. We hope 
to get further funding from the NHS Regional Office. We aim to get funding from the 
Medical Research Council for the main part of the trial. This is the organisation 
through which the government funds medical research.
Who has reviewed the study?
The South Tees Ethics Committee has approved this study.
Contact for Further Information.
Miss Jane McNeil
Lead Nurse, Gynae Oncology
Ward 19
James Cook University Hospital 
Marton Road 
Middlesbrough 
TS43BW
01642 282418
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Appendix 4.2 -  consent form
South Tees Hospitals
NHS Trust 
Follow-up In Gynaecological Oncology
Name of Researchers: Miss Fiona M Kew, Specialist Registrar, Gynae Oncology
Mr Derek J Cruickshank, Consultant Gynae Oncologist 
Mr James Nevin, Consultant Gynae Oncologist 
Dr Adrian J Rathmell, Consultant Clinical Oncologist
Please initial box
1 . I confirm that I have read and understand the information sheet dated 
June 2001 for the above study and have had the opportunity to ask 
questions
2 . I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical
care or legal rights being affected
3. I agree to take part in the above study.
I I
name of patient date signature
I I
name of person taking date signature
consent (if not researcher)
I I
researcher date signature
□
□
□
rzzza
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Appendix 4.3 -  patient information leaflet
Patient Information Leaflet
Patient Information Leaflet -  After Cancer of the Endometrium
Introduction
You have now completed treatment for the cancer that you had. Hopefully you will 
not have any further problems in the future, but sometimes people do. The role of 
follow-up after treatment is to deal with problems when they arise and arrange any 
further treatment, if necessary. As part of the trial that you agreed to help us with, you 
have been selected to have patient-initiated follow-up. This is instead of the 
traditional practice of routine appointments, which do not always arrive when you 
actually need help.
What is Patient-Initiated Follow-up?
This means that we will see you as and when you think it is necessary, rather than 
bringing you back to the hospital on a routine basis. Problems may be caused by the 
treatment itself, or by the return of the cancer or, very commonly, have nothing to do 
with the cancer. In order to help you decide when (or if) you need seeing we have 
written this leaflet, which gives details of how to get hold of us. It also gives you some 
guidance on when you may need to contact us
Phone Line
There is a new telephone line especially for ladies that are participating in this trial. 
The telephone number is xxxxxxxxxx. A trained nurse will be available to answer
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your call between xxxxxxxxxxxxxxxxxxxxxxxxxxxx. At all other times there is a 
confidential answer phone, where you can leave a message. We will return your call 
within two working days.
When to use the phone line
You should phone us if you have symptoms that may indicate that the cancer has 
returned, or if you have ongoing problems from your treatment that you need help 
with.
We have listed below some of the more common symptoms people get if their cancer 
returns. However, it is important to remember that most people will not experience 
any one of these symptoms, and that even if you have all of them it does not 
necessarily mean that the cancer has come back.
If you get any of the following symptoms for no apparent reason, and they last for 
more than a few days, we recommend that you phone us for further advice:
• Bleeding from the vagina (‘front passage’)
• Bleeding from the rectum (‘back passage’)
• Bleeding after sexual intercourse, if this is new
• New aches and pains in the abdomen (‘stomach’) or pelvis
• Vaginal discharge
• Weight loss without dieting or exercise
• Feeling generally unwell
• Any new lumps or masses in the abdomen (‘stomach’)
Some people have problems with their bowels, water works or with sexual 
intercourse after treatment. If you have these problems and need help, then feel free 
to call us (or your GP if you prefer).
When should I see my General Practitioner (GP)?
It is important to remember that you will still get coughs, colds, aches and pains just 
like anybody else. Your General Practitioner (GP) will be happy to treat any such 
problems. If they are concerned about your symptoms when they see you, they can 
also contact us and arrange for you to be seen.
Remember, if you are uncertain about the importance of any of the symptoms you 
are having, you should contact us or your GP.
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What information will we need when you phone?
Your name 
Your date of birth
A daytime telephone number (we will need this even if you phone when the phone 
line is manned in case we need to contact you further).
Details of your symptoms -  you may find it helpful to make a list.
What will happen after you have phoned us?
Any problems you are having may be caused by the treatment itself, or by the return 
of the cancer or, very commonly, have nothing to do with the cancer. Often, we need 
to see you in order to decide which of these is the case. When you phone, we will 
suggest one of the following:
1. A clinic appointment
We may wish to see you at the hospital to assess you further. Should we feel this is 
necessary, we will give you an appointment to come to the clinic, or possibly the ward, within 
five working days.
2. A visit to the GP
In some cases it may be more appropriate for you to see your GP for you problems. If your 
GP has any concerns he/she can always contact us for further help.
3. Reassure you that nothing further is needed
If we, and you, are happy that no further action is needed, we may suggest that you just keep 
an eye on things.
We will keep a record of your phone call, for future reference.
PHONE LINE NUMBER: xxxxxxxxxxxx 
This number will be staffed during the following times:
A confidential answer phone is available at all other times.
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Chapter 5 -  Conclusions
It is estimated that in the UK approximately 1.2 million people are currently 
living with and beyond a cancer diagnosis90, and the evidence suggests that 
many people suffer adverse physical and psychological consequences in the 
time following treatment that generally go unrecognised. People following 
cancer treatment will universally feel distressed at some point in their illness 
trajectory. As increasing numbers of medical therapies develop in treating 
cancer, more people are cured but also many more are living longer with 
disease. Therefore, cancer is increasingly being viewed as a chronic illness91. 
This has important consequences when considering the role and function of 
follow up in cancer services.
The government has recently promised to ‘reshape the health services around 
the needs and aspirations of patients1.92 A commitment has been made to 
seek and listen to the views of patients and act on them in order to provide 
care that is tailored to the needs of the individual93. In order to provide 
individualised care it is vital to understand the views and needs of individual 
patients. This in turn will allow the assessment of existing follow up regimens 
and the planning of alternative strategies for the ongoing care of these 
women. What qualitative work has been done has shown that women find 
routine visits to the hospital reassuring, especially if they are experiencing 
unexpected symptoms, although the reassurance only lasts for short 
periods20. The qualitative work in chapter 3 would seem to indicate that the 
women become emotionally reliant on these bursts of reassurance and that 
they value highly the process of attending clinic visits at the hospital. This was 
confirmed by the wider survey reported in Chapter 3.
Whilst there have been moves with other cancer sites to use different forms of 
follow-up such as nurse led94 or General Practitioner led95, practice in 
gynaecological cancers still follows the traditional secondary/tertiary care 
model. Although treatment has been individualized, follow up has remained 
standardised. There continues to be a one-size fits all approach to follow up
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after gynaecological cancers. In 1999 the Haward report65 stated that there 
was no evidence to support the routine follow-up of women in remission after 
a gynaecological cancer, and suggested that follow-up of women after 
endometrial cancer should not be considered mandatory. However, as 
demonstrated by the survey of practice in chapter 2 , there is very little 
variation between different Gynaecological cancer centres in their follow up 
regimens, and no suggestion that such care is individualised. This may be 
because of a lack of good quality evidence on the effectiveness of follow up to 
improve any type of outcome and no assessment of the best regimens for 
follow up, as has been shown in the literature review in chapter 1. Therefore 
clinicians stick to what they are used to.
Given this paucity of evidence demonstrating any benefit from follow up of any 
description, further research is strongly indicated. This should be in the form 
of a prospective randomised trial, since this is the only way to eliminate the 
possibility of length time bias inherent in all the retrospective studies reported 
in gynaecological cancers. Furthermore the trial must be adequately powered 
to ensure that a clinically significant difference in outcome between different 
types of follow up is not missed.
Proposed Trial
The null hypothesis for a trial should be that there is no benefit from follow up 
of any kind. As such it should compare no follow up with one or more different 
types of follow up.
In spite of this, given the information from chapter 3 on women’s views, it 
seems unlikely that a trial comparing no follow up to standard follow up would 
be acceptable to the target population. Additionally, the survey of practice in 
chapter 2  has demonstrated that routine clinic follow up for five years after 
treatment remains standard practice for women who have had a 
gynaecological cancer. As such, the feasibility of recruitment to a trial that has 
no follow up as one arm has to be questioned.
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The pragmatic approach is, therefore, to design a trial that compares minimal 
acceptable follow up with current standard practice (as defined from the data 
collected in chapter 2). Blinding of participants and clinicians is not feasible 
given the nature of the study.
The control arm would be that of patient initiated follow up as described in 
chapter 4. Women would have open access to the Gynaecological Oncology 
team via the use of a telephone line or by accessing appointments through 
their General Practitioner. No routine appointments will be made after 
randomisation. Women will be given advice regarding symptoms that may 
indicate recurrence and when to contact the hospital. The use of open access 
via a telephone line seems to give women sufficient reassurance that they can 
access the system if they have a problem, rather than leaving them with no 
follow up or support what so ever. This is in keeping with information from 
Bradley et al20 that shows that one of the things that women value the most 
from follow up is the access to specialist services if they develop problems. 
However, it should be noted that this reduced level of follow up in the patient- 
initiated arm may have contributed to the low level of recruitment in the 
feasibility study.
The intervention arm would be that of standard follow up as determined by the 
survey of practice. Women would be given routine clinic appointments at three 
monthly intervals in the first year, four monthly intervals in the second year, six 
monthly intervals in the third and fourth years and then an annual visit in year 
five.
Further trials should be designed to compare follow up for women who have 
been treated for cervical and vulval cancer. This is appropriate for these three 
cancers because there are potentially curative salvage treatments, so an 
intervention (follow up) that detects recurrence earlier and therefore enables 
treatment to be given earlier has the potential to improve survival.
This proposal differs from the feasibility study in two crucial ways. Firstly these 
three different cancer sites have been separated. Following consideration of
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the feasibility study it is obvious that the women who suffer from these three 
cancers have differing epidemiological and aetiological factors that may have 
a differential influence on outcome and as such it is not appropriate to pool 
results across the different cancer sites.
Secondly ovarian/fallopian tube/primary peritoneal carcinomas have been 
excluded. Data published after the completion of the feasibility study22 have 
shown that there is no survival benefit from treatment of recurrent ovarian 
cancer with chemotherapy at biochemical relapse, as opposed to at 
symptomatic relapse. As such it is difficult to justify a further randomised trial 
in this group at this point, where survival and detection of recurrence are the 
main endpoints. Further work in women who have been treated for ovarian 
cancer would be better geared at looking at the forms of support and follow up 
they would wish for in order to deal with the physical and psychological after 
effects of their disease and treatment. This would lend itself to trialing of 
different types of follow up with the outcomes geared around patient 
satisfaction, quality of life and psychological well-being. This study has not 
been considered further within the remit of this thesis.
Inclusion and Exclusion Criteria
The trial should compare the two different types of follow up in women who 
have completed treatment for endometrial cancer and do not require follow up 
for any reason. All stages and histological subtypes will be included. Women 
who require further follow up for any reason (ongoing symptoms, side effects 
of treatment) will be excluded. Women without access to a telephone will also 
be excluded. Women who cannot read and write English will be excluded 
because they will not be able to complete the quality of life assessments.
Women who have been treated previously for another cancer will also be 
excluded because they may have ongoing follow up and will have 
experienced other regimens and approaches to follow up which may affect 
their views.
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Outcome Measures
Primary Outcome Measure
The primary outcome measure should be survival -  both absolute and quality 
adjusted using the EQ5D96. About 85% of women treated for endometrial 
cancer survive for three years. An expert group of gynaecological oncologists 
regarded an absolute change of 5% or greater in three-year survival as 
clinically important.
To detect a 5% absolute change in three-year survival (to more than 90% or 
less than 80%) with 80% power when using a 5% significance level needs 
1800 patients. A two-tailed test has been used since it is possible that a 
clinically important difference could be seen in either direction. Allowing for 
1 0 % complete loss to follow-up recruitment would need to be a total of 2 0 0 0 . 
Patients’ time in the trial will range between 1.5 and 4.5 years. Follow up 
research questionnaires will be completed after 6  and 1 2  months, and two, 
three and four years. Allowing for death and other loss to follow-up, it is 
estimated that at least 1000 (50%) will respond to their planned final 
questionnaire. This will yield 90% power when using a 5% significance level 
to detect a standardised difference of 0 . 2  (regarded as the boundary between 
small and trivial change) 97 in the secondary outcome measures. Because the 
1000 patients who respond, and the 300 patients who die, all contribute to the 
estimation of quality-adjusted survival (QALYs), this power will increase to 
95% when comparing QALYs. (Calculation performed by Professor I T 
Russell, see appendix 1).
Data on survival will be collected within the trial and checked against data in 
the cancer registry.
Two studies of breast cancer have tested the feasibility of recruiting patients 
into trials comparing different follow-up packages. Gulliford et al58 recruited 
93% of women treated for breast cancer to a trial comparing reduced follow-
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up with standard follow-up. Grunfeld et al95,98 recruited 6 6 % of such women 
to a trial comparing follow-up in general practice with standard follow-up. 
Even the unfunded feasibility study randomised 31% of eligible patients 
treated for gynaecological cancer between routine and patient-initiated follow- 
up. These three studies suggest that an adequately resourced trial can recruit 
at least 50% of eligible patients. Thus to recruit 2000 patients over 3 years 
will require cancer centres which together treat 1350 eligible patients a year. 
This we equates to at least 27 centres who treat an annual average of 50 
eligible patients with endometrial cancer.
Secondary Outcome Measures
1. Disease Free Survival. The full project should, as an interim outcome, 
assess the rate of detection of recurrence between the two arms. If a 
difference in time to detection of recurrence is shown, then the trial 
should be continued to test for differences in survival. If there is no 
difference in time to detection of recurrence it is unlikely that any 
difference would be found in survival.
2. State Trait Anxiety Inventory99. It clearly differentiates between the 
temporary condition of “state anxiety" and the more general and long­
standing quality of “trait anxiety" which is useful in a setting where there 
are potential stress points (follow up visits) as opposed to an ongoing 
problem (living beyond a cancer diagnosis).
3. Beck Depression Inventory100. This should be used in preference to the 
hospital anxiety and depression scale because it has been shown to 
work in non-psychiatric patients and discriminates subtypes of 
depression and differentiates depression from anxiety101.
4. Quality of Life Measures. As shown in the feasibility study, women are 
willing to complete several quality of life tools. The EQ5D is mentioned 
above. It is best to use disease-specific tools as well as a more general 
quality of life tool. Therefore the EORTOC QLQ-C30 (a generic cancer 
quality of life measure) should be used (as in the feasibility study)102. A
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specific module for use in women with endometrial cancer has now 
been developed (EORTOC QLQ-EN24)103 and should also be used.
5. Patient satisfaction. There are multiple methods by which to measure 
patient satisfaction. However, in the first place a study using qualitative 
interview methodology is appropriate since this will allow collection of in 
depth information on the feelings of the women about the different 
types of follow up. A small purposive sample will be identified from both 
arms of the trial and data compared. This data should then be 
triangulated by using a specifically designed and validated 
questionnaire survey of all women participating in the study. Further 
information will also be collected by way of exit interviews for women 
who choose to leave the trial in order to determine if withdrawal is 
linked to dissatisfaction with the mode of follow up they have 
experienced.
6 . Economic. Full economic evaluation of quality adjusted life years will be 
required in the event of a difference in survival being demonstrated. A 
costs analysis for each mode of follow up will be produced. This will 
need to include number of clinic appointments, cost of the telephone 
line, length of appointments, along with medical and surgical 
interventions. It will also need to collect information on the use of 
primary care, since there is a risk that provision of less secondary care 
may simply mean that women attend to see their General Practitioner 
more often.
All questionnaires will be administered at randomisation and then at six, 12, 
24, 36 and 48 months after recruitment. Postal reminders will be sent after two 
and six weeks to non-responders and then they will be contacted by 
telephone if they still have not responded.
If a significant difference in survival is demonstrated, this will allow healthcare 
providers to provide the most effective form of follow-up to its patients. If there
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is no significant difference in survival, then it will allow the service to decide 
the most effective type of follow-up based on cost, use of resources in primary 
and secondary care and the views and experiences of the patients 
themselves. Furthermore, a different model of follow up has the potential to 
improve capacity, by reserving the use of resources for those who need it, and 
to improve patient access, through the use of the telephone line. Overall such 
a trial would provide vital evidence to make significant changes in the way 
healthcare is delivered.
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Please note: The first stage of HTA Clinical Trials assessment will only use this section (Section C) of the 
form. You must complete this section of the form in anonvmised format - you must not include any 
Information that enables any Individual or team associated with your application to be identified.
Section C: Justification of Project Proposed
1. Specification of research question:
Please state in one sentence the research question to be addressed
In patients who have completed treatment for endometrial cancer, which of self-initiated or routine follow-up is 
the more effective and the more cost-effective?
2. Importance of the health problem to the NHS:
Please describe the frequency of the health problem in the population and its impact on patients and the NHS.
Across the UK there are about 7000 newly diagnosed cancers of the endometrium each year Five-year survival 
rate for Stage I tumours is about 85%. Routine follow-up of these patients after treatment of their cancers 
remains standard This assumes that detecting recurrent cancer before symptoms develop will permit earlier 
treatment and improve survival rates However there is no randomised controlled trial (RCT) that tests whether 
routine follow-up affects survival rates in gynaecological oncology Furthermore 4 RCTs in breast cancer show 
no significant survival benefit from intensive follow-up compared with little or no follow-up In contrast 
meta-analysis has shown that intensive follow-up after curative resection for colorectal cancer improves survival 
relative to routine follow-up In lung cancer nurse-led follow-up was acceptable to patients and generated better 
functional outcomes Given the absence of evidence for routine visits, and pressure from NHS priorities, there 
is a strong case for an RCT to evaluate whether health technology comprising training and full support for 
self-initiated follow-up in endometrial cancer is effective or cost-effective or both This case has the full support 
of the NCRI Gynaecological Cancer Studies Group, who also endorse this application
3. A description of the technology and its possible effect on health status:
You should also discuss current and projected use in the NHS, with approximate costs.
We have developed, & tested the feasibility of, a protocol for training patients to initiate their own follow-up, and 
leaflets for patients & GPs about the symptoms of recurrence, all suitable for use across the NHS. So 
experimental patients will receive a structured briefing from a Nurse Specialist & the number of a telephone help 
line staffed by their local centre Calls to the help line, by patients or their GPs, generate clinic appointments 
whenever appropriate and without limit Participating gynaecological oncology centres will also offer GPs 
continuing education on the post-treatment care of endometrial cancer Our survey of current practice showed 
consensus around follow-up intervals of 3 months for the 1st year, 4 months for the 2nd year, and 6 months for 
the third year and then annually until discharge at 5 years Building on this survey we have also developed 
guidelines for routine follow-up in secondary care (notably a minimum of 6 visits over 3 years), thus ensuring 
general consistency without undermining local autonomy Feasibility studies in two distinct centres suggest that 
the new technology is at least as effective as usual treatment & may save costs
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Please note: The first stage of HTA Clinical Trials assessment will use this section (Section C) of the form 
only. You must complete this section of the form In an anonymlsed format - there must not be any 
information that enables any individual or team associated with your application to be identified.
4. Summary of the current evidence:
Please describe the current knowledge and outline other research taking place in this area You should discuss how 
the proposed research will add to the existing evidence base. You must also consider any relevant published or 
ongoing HTA programme projects
We conducted a systematic review of follow-up for gynaecological cancer and searched MeSH terms for [genital 
neoplasms] & [female] & [aftercare/ambulatory care/follow-up studies/population surveillance/primary health care] 
and text for a wide range of synonyms of these terms Of the 13000 resulting references, only 18 retrospective 
studies of women treated for cancer rigorously reported on survival Of 9 that studied endometrial cancer, only 1 
reported a survival benefit from routine follow-up; however it did not control for the bias inherent in retrospective 
studies Repeating the same search strategy recently identified no useful extra references or current RCTs In 
these circumstances we expect the proposed ROT to dominate the literature & either to change or to confirm 
current practice, for which there is little rigorous evidence
5. What outcomes will be measured?:
Primary: Survival over mean of 3 years -  both absolute & adjusted by EQ5D to yield quality-adjusted life-years 
2ndary after 6,12,24,36 & 48 months: Quality of life -  generic (EORTC-QLQ-C30. which assesses emotional, 
functional, physical & social well-being in cancer) & site-specific [EORTC-QLQ-EN34, recently developed by 
Quality Of Life Group of European Organisation for Research & Treatment in Cancer (EORTC) specifically for 
endometrial cancer]; anxiety & depression -  State-Trait Anxiety Inventory & Beck Depression Inventory; 
progression-free survival; cancer-specific symptoms; patient attitudes to follow-up especially acceptability & 
preferences. Costs from perspective of NHS & patients patients will use Client Service Receipt Inventory to report 
NHS resource use in secondary & primary care, focusing especially on use of primary care to advise on, & initiate, 
contact with secondary care; they will also report personal costs
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Please note: The first stage of HT A Clinical Trials assessment will use this section (Section C) of the form 
only. You must complete this section of the form In an anonymIsed format - there must not be any 
information that enables any individual or team associated with your application to be identified.__________
6. Summary for the Non-Expert
Please provide a summary Of sections 1 to 5. This summary should enable the non-expert reviewer to  understand how the proposal 
ad re sse s  a question im portant to  the NHS, how and where the research wi# be carried out, what outcom es w ill be used to  assess the success 
o f the research, what if  any, are the eth ical issues involved m th is study and arrangem ents fo r handling these, why th is  team  is  weX placed to 
carry out the research and provide justifica tion  for the costs requested (including any NHS costs).
Aim: To compare the effectiveness & cost-effectiveness of patient-initiated follow-up after completed 
treatment for endometnal cancer with routine follow-up in secondary care 
Objective: To evaluate whether these regimes differ in survival & cost per quality-adjusted life year 
Design: Pragmatic RCT collecting patient preferences as potential prognostic variable 
Health technologies being assessed: Experimental patients receive training, written information 
especially about symptoms of recurrence, phone number giving direct access to outpatient clinic, & 
possibly access to patient-initiated decision support software; control patients receive current best 
practice, that is guideline-based routine follow-up.
Setting: 30 gynaecological oncology centres with 1500 eligible new patients / year 
Patients: 2000 women treated for endometrial cancer over 3 years
Outcomes: Survival over mean of 3 years; quality-adjusted life-years: generic & cancer-site-specific 
quality of life after 6,12,24, 36 & 48 months.
Ethical issues: Though there could be concern that there is political motivation to cut costs, our 
feasibility studies suggest that patient-initiated follow-up is as effective as usual care.
Team: National collaboration of gynaecological & medical oncologists, GP, cancer nurse & trialists 
Research costs: £1000 per recruited patient represents good value for money (no net NHS costs).
Please note: The following sections (D onwards) of the form are used (along with those earlier) In the 
second stage of the assessment process where the study design and scientific merit are also scrutinised. 
You should provide a clear explanation of your intended study.
Section D: Objectives
Please provide a clear summary of your research objectives.
We aim to evaluate whether patients who have completed treatment for endometnal cancer fare better or worse if, 
rather than routine follow-up in secondary care, they receive training in initiating their own follow-up together with the 
number of a telephone help-line
Thus our research objectives are:
1 to estimate whether these two regimes differ in effectiveness as measured by survival, quality of life (both genenc 
and cancer-site-specific) and quality-adjusted survival over an average of 3 years from completing treatment:
2 to evaluate whether these two regimes differ in cost-effectiveness as measured by cost per quality-adjusted 
life-year when the EQ5D fEuroQol’) is the criterion for quality of life;
3 to test for differences in long-term survival and resource use if the trial shows that patient-initiated follow-up 
generates benefits over an average of 3 years from completing treatment -  by designing the trial to permit an 
extension focusing on routine data
4 to study the process of patient-initiated follow-up, both quantitatively & qualitatively, with a view to refining it for 
future implementation
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Section E: Summary of Project
Please provide a summary of your proposed research using the headings listed in the Guidance Notes
Background -  routine follow-up in hospital of patients treated for endometnal cancer is standard This 
assumes that detecting recurrent cancer before symptoms develop will permit earlier treatment & 
improve survival rates While some argue that hospital follow-up is reassuring for patients, routine 
appointments can be source of stress & delay However there is no randomised controlled trial 
(RCT) testing whether routine follow-up affects survival rates in gynaecological cancer 
Design: Pragmatic RCT -  traditional rather than patient preference’, but collecting patient 
preference as potential prognostic variable 
Health technologies being assessed: Patient-initiated follow-up -  patients receive training, info 
especially about symptoms of recurrence, phone number for immediate access to outpatient clinic, & 
possibly access to patient-initiated decision support software: care as usual -  patients receive 
routine follow-up in secondary care, based on consensual guidelines.
Target population: Women completing curative treatment for endometnal cancer.
Setting 30 gynaecological oncology centres with 1500 eligible new patients / year 
Sample size: 2000 randomised equally between technologies About 85% of women treated for 
endometrial cancer survive for 3 years. To detect 5% change in 3-year survival (to more than 90%
or less than 80%) with 80% power when using 5% significance level needs 1800 patients Allowing
to complete questionnaires after 6 & 12 months, and 2,3 & 4 years Allowing for death & other loss 
to follow-up, we estimate that at least 1000 (50%) will respond to their planned final 
questionnaire This will yield 90% power when using a 5% significance level to detect standardised 
difference of 0.2 (usually taken as boundary between small & trivial change) in secondary outcome 
measures -  EORTC-QLQ-C30 & EN34. Because the 1000 patients who respond, & the 300 patients 
who die, all contnbute to the estimation of quality-adjusted survival (QALYs), this power will 
increase to 95% when companng quality-adjusted life-years (QALYs)
Measurement of outcomes 
Primary: survival over mean of 3 years- absolute & adjusted by EQ5D to give QALYs 
Secondary Quality of life at 6,12,24,36 & 48 months -  generic (EQRTC-QLQ-C30, which assesses 
emotional, functional, physical & social well-being in cancer) & site-specific (EORTC-QLQ-EN34); 
anxiety & depression -  State-Trait Anxiety Inventory & Beck Depression Inventory; progression-
Measurement of costs from perspective of NHS & patients: patients will use Client Service Receipt 
Inventory to report NHS resource use in 2ndary & primary care, focusing especially on time in 
primary care to advise on, & initiate, contact with 2ndary care: they will also report personal costs 
Project timetable set-up -1 2  months; recruitment -  36 months; follow-up ranging from 18 months 
for final recruits to 42 months for initial recruits; definitive analysis & report -  6 months
for 10% complete loss to follow-up, we aim to recruit total of 2000 Patients’ time in the trial will 
range between 1.5 and 4.5 years, depending on whether they join late or early We shall ask them
free survival; cancer-specific symptoms: patient attitudes to follow-up especially acceptability & 
preferences
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Section F: Team Expertise
Please provide a dear account of the team assembled and the skills and expertise each member will provide
The FIGURE tnal development group (TDG) represents a strong collaboration between gynae oncology, led by 
FMK. & dinical tnals expertise, led by ITR The TDG comprises a research-active team of 15 including 7 who will 
become applicants on any full application -  Richard Edmondson, John Kirwan & John Murdoch (gynae oncologists) 
Rhiannon Tudor Edwards (health economist) David Ingledew (health psychomethdan) Richard Neal (GP cancer 
specialist) & Adrian Rathmell (medical oncologist) Of 8 current applicants DJC, FMK & AJN are gynae oncologists 
who have published extensively on follow-up in gynae cancer JAG is an academic medical oncologist who has 
published extensively on translational issues HCK is an eminent academic gynae oncologist who chairs the NCRI 
Gynaecological Cancer Studies Group AL is a well-published cancer nurse leading research into follow-up in 
ovarian cancer AJN led, & AL was a member of, the EORTC Quality Of Life Subgroup who developed the 
EORTC-QLQ-EN34, the new HRQOL module specific to endometrial cancer & due for use in FIGURE ITR & RhW 
are experienced trialists ITR was previously Diredor & currently Non-Executive Director of the North Wales 
Organisation for Randomisation Trials in Health (NWORTH -  Registered Clinical Trials Unit in receipt of CTU 
infrastructure funding from Welsh Assembly Government!) & Diredor of WWORTH, the West Wales equivalent 
(currently applying for registration as CTU in collaboration with NWORTH); & RhW is executive manager of 
NWORTH Thus the proposed trial has access to a full range of Standard Operating Procedures & trials expertise
Please provide details about any related (planned or active) grants held by any member of your research team in 
this or similar research areas You should include a clear explanation of how the research being proposed in this 
application will fit.
ITR has finished academic administration to focus on his portfolio of 7 large trial grants -  4 funded by NIHR HT A 
Programme (COGNATE, COnStRUCT, FolATED & RemCare) & 3 programme grants, 2 from NIHR (DemCare & 
SHIELD) & 1 from Wellcome Trust (Staying Well After Depression). This portfolio spans the collaboration between 
the North (NWORTH) & West Wales Organisations for Randomised Trials in Health (WWORTH) RhW manages 
NWORTH and its core grant from the Welsh Office for R&D in health & social care Together all these grants 
provide evidence of effective collaboration in clinical trials between Bangor & Swansea AJN & AL hold a grant from 
the European Commission for the continuing validation of the EORTC-QLQ-EN34
Section G: Network Collaboration
Please say with which of the UK Clinical Research Networks (http://www ukcm.org.uk) you intend to link for this 
research
National Cancer Research Institute (including Gynae Cancer Studies Group), Comprehensive Local Research 
Networks, Clinical Research Collaboration Cymru (including North & West Wales Organisations for Randomised 
Trials in Health)
Please list any benefits you may have identified from working with the network(s).
In their different ways these 3 types of network have all contributed, & are continuing to contribute, to the 
unprecedented growth in clinical research across the United Kingdom Benefits include major improvements in 
resources, professionalism, morale & esteem The only real threat lies in the danger that, when the recent growth 
stabilises, consolidation will take time & effort That would be a small price to pay for the spectacular advances over 
the past 20 years
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